<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1305245278
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRECEDEX 100 MCG -ML IV. VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXMEDETOMIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        102.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05CM18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PRECEDEX (dexmedetomidine hydrochloride) injection (100 mcg/mL) is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution.</p><p>PRECEDEX (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection (4 mcg/mL) is a sterile, nonpyrogenic ready to use solution suitable for intravenous infusion.</p><p>&nbsp;</p><p><strong>Indications and Usage:</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Intensive Care Unit Sedation</strong></p><p>&nbsp;PRECEDEX can be used as a sedative (calming agent) if adults need to be calm or sleepy in the Intensive Care Unit whilst they are being ventilated (on a breathing machine). It may be given as an infusion up to 24 hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Procedural Sedation</strong></p><p>PRECEDEX&nbsp; can be given to adults prior to an operation if they are not on a ventilator (breathing machine) if it is required for the procedure or surgery that they be sleepy and calm.</p><p>PRECEDEX&nbsp; can be given to pediatrics aged 1 month to less than 18 years prior to or during non-surgical operation if they are not on a ventilator (breathing machine) if it is required for the procedure or surgery that they be sleepy and calm.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Precedex</strong></p><p>You must not be given PRECEDEX</p><p>- if you are allergic to dexmedetomidine or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before using this medicine</p><p>&nbsp;</p><p>Drug Administration</p><p>PRECEDEX should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of PRECEDEX, patients should be continuously monitored while receiving PRECEDEX.</p><p><strong>&nbsp;</strong></p><p><strong>Hypotension, Bradycardia, and Sinus Arrest</strong></p><p>Clinically significant episodes of bradycardia and sinus arrest have been reported with PRECEDEX administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.</p><p>Reports of hypotension and bradycardia have been associated with PRECEDEX infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of PRECEDEX, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because PRECEDEX has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of PRECEDEX-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.</p><p>Caution should be exercised when administering PRECEDEX to patients with advanced heart block and/or severe ventricular dysfunction. Because PRECEDEX decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients.</p><p>In clinical trials where other vasodilators or negative chronotropic agents were co-administered with PRECEDEX an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with PRECEDEX.</p><p><strong>&nbsp;</strong></p><p><strong>Transient Hypertension</strong></p><p>Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of PRECEDEX. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.</p><p><strong>&nbsp;</strong></p><p><strong>Arousability</strong></p><p>Some patients receiving PRECEDEX have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.</p><p><em>&nbsp;</em></p><p><strong>Tolerance and Tachyphylaxis</strong></p><p>Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions</p><p>&nbsp;</p><p><strong>Hyperthermia or Pyrexia</strong></p><p>PRECEDEX may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue PRECEDEX if drug‑related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalize.</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic Impairment</strong></p><p>Since PRECEDEX clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function.</p><p>&nbsp;</p><p><strong>Risk of Mortality</strong></p><p>Use of dexmedetomidine greater than 24&nbsp;hours has been associated with an increased mortality in critically ill adult intensive care unit (ICU) patients 63.7&nbsp;years of age and younger compared to usual care.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Pediatric Use</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sedation for Non-Invasive Procedures</strong></p><p>The safety and efficacy of PRECEDEX have been established in pediatric patients 1&nbsp;month to less than 18&nbsp;years of age for sedation during non-invasive procedures. Use in this age group is based on one randomized double-blind, dose-ranging safety and efficacy trial in non-intubated pediatric patients 1 month to less than 17&nbsp;years of age who required sedation prior to undergoing MRI scans <em>[see Clinical Studies]</em>. An increase in frequency of bradypnea, bradycardia, hypertension and hypotension was observed in pediatric patients treated with PRECEDEX <em>[see 4.8 Undesirable effects]. </em>The overall safety profile of PRECEDEX in pediatric patients was consistent with the known safety profile in adults<em> [see 4.8 Undesirable effects]</em>.</p><p>The safety and effectiveness of PRECEDEX have not been established in pediatric patients less than 1 month of age.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ICU Sedation</strong></p><p>The safety and efficacy of PRECEDEX have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of PRECEDEX for this patient population.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric Use</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Intensive Care Unit Sedation</strong></p><p>A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of PRECEDEX. Therefore a dose reduction may be considered in patients over 65 years of age.</p><p>An increased mortality risk has been seen for critically ill adult ICU patients 63.7&nbsp;years of age and younger when the exposure to dexmedetomidine was greater than 24&nbsp;hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Procedural Sedation</strong></p><p>A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75&nbsp;years of age and over. Hypotension occurred in a higher incidence in PRECEDEX-treated patients 65&nbsp;years or older (72%) and 75 years or older (74%) as compared to patients &lt;65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and PRECEDEX </strong></p><p>Tell your doctor or nurse if you are taking have recently taken or might&nbsp; take any other medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anesthetics, Sedatives, Hypnotics, Opioids</strong></p><p>Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between PRECEDEX and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX or the concomitant anesthetic, sedative, hypnotic or opioid may be required.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Neuromuscular Blockers</strong></p><p>In one study of 10 healthy adult volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Interaction with CYP Enzymes</strong></p><p>Inhibition of CYP enzymes including CYP2B6 by dexmedetomidine has been studied in human liver microsome incubations. In vitro study suggests that interaction potential in vivo exists between dexmedetomidine and substrates with dominant CYP2B6 metabolism.</p><p>&nbsp;</p><p>The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinal products causing these effects, for example beta-blockers, although additional effects in an interaction study with esmolol were modest.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong>Pregnancy </strong></p><p><u>Risk Summary</u></p><p>Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta.</p><p>In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8&nbsp;mcg/kg/day.</p><p>Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning <em>(see Data)</em>.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%, respectively.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e. decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6&nbsp;to 15). No malformations were reported.</p><p>No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD&nbsp;6 to 18).</p><p>Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8&nbsp;mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD&nbsp;16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32&nbsp;mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD&nbsp;6&nbsp;to 7) to weaning (PND&nbsp;21).</p><p>&nbsp;</p><p>In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.</p><p><strong>&nbsp;</strong></p><p>Lactation</p><p><u>Risk Summary</u></p><p>Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration <em>(see Data)</em>. There is no information regarding the effects of dexmedetomidine on the breastfed infant or the effects on milk production. Advise women to monitor the breastfed infant for irritability. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for PRECEDEX and any potential adverse effects on the breastfed infant from PRECEDEX or from the underlying condition.</p><p><u>Data</u></p><p>In two published clinical studies, a total of 14 women were given intravenous dexmedetomidine 6 mcg/kg/hour for 10&nbsp;minutes after delivery followed by continuous infusion of 0.2&ndash;0.7 mcg/kg/hour. Breast milk and maternal blood samples were collected at 0, 6, 12, and 24 hours after discontinuation of dexmedetomidine. Plasma and milk dexmedetomidine concentrations were detectable up to 6 hours in most subjects, up to 12&nbsp;hours in one subject and undetectable in all at 24 hours. The milk-to-plasma ratio from single paired maternal milk and plasma concentrations at each time point ranged from 0.53 to 0.95. The relative infant dose was estimated to range from 0.02 to 0.098%.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Administration Instructions</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX dosing should be individualized and titrated to desired clinical response.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX is not indicated for infusions lasting longer than 24 hours.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX should be administered using a controlled infusion device.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Recommended Dosage</strong></p><p><strong>Table 1: </strong><strong>Recommended Dosage in Adult Patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>INDICATION</strong></p></td><td style="vertical-align:top"><p><strong>DOSAGE AND ADMINISTRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients:</strong> a loading infusion of one mcg/kg over 10 <strong>minutes</strong>.</p><p><strong>For adult patients being converted from alternate sedative therapy: </strong>a loading dose may not be required.</p><p><strong>For patients over 65 years of age:</strong> a dose reduction should be considered.</p><p><strong>For adult patients with impaired hepatic-function: </strong>a dose reduction should be considered.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients: </strong>a maintenance infusion of 0.2 to 0.7 mcg/kg/<strong>hour</strong>. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation.</p><p><strong>For patients over 65 years of age: </strong>a dose reduction should be considered<em>.</em></p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients: </strong>a loading infusion of one mcg/kg over 10 <strong>minutes</strong>. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5&nbsp;mcg/kg given over 10 <strong>minutes</strong> may be suitable.</p><p><strong>For awake fiberoptic intubation in adult patients: </strong>a loading infusion of one&nbsp;mcg/kg over 10 <strong>minutes</strong>.</p><p><strong>For patients over 65 years of age:</strong> a loading infusion of 0.5 mcg/kg over 10&nbsp;<strong>minutes</strong><em>.</em></p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients:</strong> the maintenance infusion is generally initiated at 0.6&nbsp;mcg/kg/<strong>hour</strong> and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<strong>hour</strong>. The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation.</p><p><strong>For awake fiberoptic intubation in adult patients: </strong>a maintenance infusion of 0.7&nbsp;mcg/kg/<strong>hour</strong> is recommended until the endotracheal tube is secured.</p><p><strong>For patients over 65 years of age: </strong>a dose reduction should be considered<em>.</em></p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 2: Recommended Dosage in Pediatric Patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>INDICATION</p></td><td style="vertical-align:top"><p>DOSAGE AND ADMINISTRATION</p></td></tr><tr><td style="vertical-align:top"><p>Initiation of Sedation During Non‑invasive Procedures</p></td><td style="vertical-align:top"><p><u>For pediatric patients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 month to less than 2 years: a loading infusion of 1.5&nbsp;mcg/kg over 10 <em><u>minutes</u></em><u>.</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 to less than 18 years: a loading infusion of 2 mcg/kg over 10 <em><u>minutes</u></em><u>.</u></p><p>Consider a reduction in dosage if clinically indicated.</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of Sedation During Non-invasive Procedures</p></td><td style="vertical-align:top"><p><u>For pediatric patients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 month to less than 18 years: the maintenance infusion is generally initiated at 1.5&nbsp;mcg/kg/<em><u>hour</u></em> and titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/<em><u>hour</u></em><u>.</u></p><p>As clinically warranted, titrate the maintenance dose to individual patient clinical response.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dosage Adjustment</strong></p><p>Due to possible pharmacodynamic interactions, a reduction in dosage of PRECEDEX or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [<em>see</em><strong> Other medicines and PRECEDEX</strong>].</p><p>Dosage reductions may need to be considered for <strong>adult</strong> patients with hepatic impairment, and geriatric patients [<em>see </em><strong>Warnings and Precautions</strong>].</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Preparation of Solution</strong></p><p>Strict aseptic technique must always be maintained during handling of PRECEDEX.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if product is discolored or if precipitate matter is present.</p><p>&nbsp;</p><p><strong>PRECEDEX Injection, 200 mcg/2 mL (100 mcg/mL)</strong></p><p>PRECEDEX must be diluted with 0.9% sodium chloride injection to achieve required concentration (4&nbsp;mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.</p><p>To prepare the infusion, withdraw 2 mL of PRECEDEX Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.</p><p><strong>PRECEDEX in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4&nbsp;mcg/mL) and 400 mcg/100 mL (4 mcg/mL)</strong></p><p>PRECEDEX in 0.9% Sodium Chloride Injection is supplied in glass containers containing a premixed, ready to use dexmedetomidine hydrochloride solution in 0.9% sodium chloride in water. No further dilution of these preparations are necessary.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Administration with Other Fluids</strong></p><p>PRECEDEX infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.</p><p>PRECEDEX has been shown to be incompatible when administered with the following drugs: amphotericin&nbsp;B, diazepam.</p><p>PRECEDEX has been shown to be compatible when administered with the following intravenous fluids:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% sodium chloride in water</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 5% dextrose in water</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 20% mannitol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Lactated Ringer&rsquo;s solution</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 100 mg/mL magnesium sulfate solution</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 0.3% potassium chloride solution</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Compatibility with Natural Rubber</strong></p><p>Compatibility studies have demonstrated the potential for absorption of PRECEDEX to some types of natural rubber. Although PRECEDEX is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.</p><p>&nbsp;</p><p><strong>If you take more PRECEDEX than you should</strong></p><p>The tolerability of PRECEDEX was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hr. The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute.</p><p>Five adult patients received an overdose of PRECEDEX in the intensive care unit sedation studies. Two of these patients had no symptoms reported; one patient received a 2 mcg/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8&nbsp;mcg/kg/hr. Two other patients who received a 2 mcg/kg loading dose over 10 minutes, experienced bradycardia and/or hypotension. One patient who received a loading bolus dose of undiluted PRECEDEX (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated</p><p><em>&nbsp;</em></p><p><strong>If you stop taking&nbsp; PRECEDEX </strong></p><p><strong>Withdrawal</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intensive Care Unit Sedation</p><p>With administration up to 7 days, regardless of dose, 12 (5%) PRECEDEX adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) PRECEDEX adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation.</p><p>In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of &lt;5%.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Procedural Sedation</strong></p><p>In adult subjects, withdrawal symptoms were not seen after discontinuation of short term infusions of PRECEDEX (&lt;6&nbsp;hours).</p><p>In pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation were seen after discontinuation of short term infusions of PRECEDEX (&lt;2 hours)</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The most frequent adverse events identified in pediatric patients during non-invasive procedure were bradypnea, bradycardia, hypertension, and hypotension</p><p>&nbsp;</p><p>The following adverse reactions have been identified during post approval use of PRECEDEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><p>Hypotension, bradycardia, sinus arrest and Transient hypertension were the most common adverse reactions associated with the use of PRECEDEX during post approval use of the drug.</p><p>&nbsp;</p><p><strong>Adverse Reactions Experienced During Post-approval Use of PRECEDEX</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>Anemia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac Disorders</p></td><td style="vertical-align:top"><p>Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Eye Disorders</p></td><td style="vertical-align:top"><p>Photopsia, visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhea, nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Chills, hyperpyrexia, pain, pyrexia, thirst</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>Hepatic function abnormal, hyperbilirubinemia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Agitation, confusional state, delirium, hallucination, illusion</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>Oliguria, polyuria</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>Hyperhidrosis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Surgical and Medical Procedures</p></td><td style="vertical-align:top"><p>Light anesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>Blood pressure fluctuation, hemorrhage, hypertension, hypotension</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of side effects:</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Discard unused portion.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life 24 months.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is dexmedetomidine hydrochloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For PRECEDEX in 0.9% Sodium Chloride Injection the other ingredient is9 mg sodium chloride in water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PRECEDEX (dexmedetomidine hydrochloride) injection 200 mcg/2 mL (100 mcg/mL) is  clear  and colourless. The strength is based on the dexmedetomidine base. 
Container	Size
Tray of 25 single dose clear glass vials	200 mcg/2 mL
(100 mcg/mL)

PRECEDEX (dexmedetomidine hydrochloride in 0.9% Sodium Chloride) injection (4 mcg/mL) is clear and colourless.  The strength is based on the dexmedetomidine base.

Container	Size
Vial	200 mcg/50 mL
(4 mcg/mL)
Vial	400 mcg/100 mL
(4 mcg/mL)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Hospira, Inc., Lake Forest, IL 60045 USA</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong></p><p>Hospira Inc, NC 27801, Rocky Mount, United states</p><p>Or</p><p>Hospira Inc., McPherson, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">بريسيدكس (هيدروكلوريد دكسميديتوميدين) للحقن (١٠٠ ميكروجرام/مل) هو محلول معقم غير مولد للحمى مناسب للتسريب عن طريق الوريد بعد التخفيف.</p><p dir="RTL">بريسيدكس (هيدروكلوريد دكسميديتوميدين) في محلول كلوريد الصوديوم بتركيز ٠٬٩ ٪ للحقن (٤ ميكروجرام/مل) هو محلول معقم غير مولد للحمى جاهز للاستخدام ومناسب للتسريب عن طريق الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي الاستعمال والاستخدام:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهدئة في وحدة العناية المركزة</strong></p><p dir="RTL">&nbsp;يمكن استخدام بريسيدكس مهدئًا (عامل تهدئة) إذا كان يجب أن يكون المرضى البالغون هادئين أو نائمين في وحدة العناية المركزة أثناء خضوعهم للتنفس الاصطناعي (وضعهم على جهاز تنفس). ويمكن إعطاؤه تسريبًا على مدار فترة تصل إلى ٢٤ ساعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهدئة الإجرائية</strong></p><p dir="RTL">&nbsp;يمكن إعطاء بريسيدكس للبالغين قبل الخضوع لعملية جراحية إذا لم يكونوا على جهاز تنفس اصطناعي، وذلك إذا كان يلزم تهدئتهم وتنويمهم للقيام بالإجراء أو الجراحة.</p><p dir="RTL">يمكن إعطاء بريسيدكس للأطفال الذين تتراوح أعمارهم بين شهر واحد وأقل من ١٨ عامًا قبل أو أثناء عملية غير جراحية إذا لم يكونوا على جهاز تنفس اصطناعي، وذلك إذا كان يلزم تهدئتهم وتنويمهم للقيام بالإجراء أو الجراحة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال بريسيدكس</strong></p><p dir="RTL">يجب عدم إعطاء بريسيدكس لك</p><p dir="RTL">- إذا كنت مصابًا بحساسية تجاه دكسميديتوميدين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;الاحتياطات عند استعمال بريسيدكس</strong></p><p dir="RTL">استشر طبيبك أو الممرضة قبل استخدام هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">استعمال العقار</p><p dir="RTL">يجب إعطاء بريسيدكس فقط بواسطة أشخاص متخصصين في إدارة حالات المرضى في وحدة العناية المركزة أو غرفة العمليات. نتيجة للآثار الدوائية المعروفة لبريسيدكس، ينبغي وضع المرضى تحت المراقبة المستمرة أثناء تلقي بريسيدكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض ضغط الدم وبطء ضربات القلب وتوقف القلب جيبي المنشأ</strong></p><p dir="RTL">تم الإبلاغ عن نوبات ذات أهمية إكلينيكية من بطء ضربات القلب وتوقف القلب جيبي المنشأ عند إعطاء بريسيدكس للمتطوعين البالغين اليافعين الأصحاء الذين لديهم ارتفاع في نشاط العصب المبهم أو عند إعطائهم الدواء بطرق مختلفة تشمل الحقن السريع عن طريق الوريد أو الحقن دفعة واحدة.</p><p dir="RTL">ارتبط تسريب بريسيدكس ببلاغات عن الإصابة بانخفاض ضغط الدم وبطء ضربات القلب. نتج عن بعض هذه الحالات وقوع وفيات. إذا استلزم الأمر تدخلًا طبيًا، فقد يشمل العلاج خفض أو إيقاف تسريب بريسيدكس وزيادة معدل إعطاء السوائل عن طريق الوريد ورفع الأطراف السفلية واستخدام عوامل رافعة للضغط. ولأن لبريسيدكس القدرة على زيادة بطء ضربات القلب الذي تُسببه محفزات العصب المبهم، ينبغي أن يكون الأخصائيون الإكلينيكيون مستعدين للتدخل. ينبغي النظر في أمر إعطاء الأدوية المضادة للأثر الكوليني عن طريق الوريد (مثل جليكوبيروليت، أتروبين) لتعديل نشاط العصب المبهم. في التجارب الإكلينيكية، كان جليكوبيروليت أو أتروبين فعالًا في علاج معظم نوبات بطء ضربات القلب التي يسببها بريسيدكس. ومع ذلك، استلزم الأمر إجراءات إنعاشية أكثر تقدمًا في بعض المرضى الذين يعانون من خلل وظيفي كبير في القلب والأوعية الدموية.</p><p dir="RTL">يجب توخي الحذر عند إعطاء بريسيدكس للمرضى الذين يعانون من إحصار قلبي متقدم و/أو خلل وظيفي بطيني شديد. ونظرًا لأن بريسيدكس يقلل من نشاط الجهاز العصبي الودي، فمن المتوقع أن يكون انخفاض ضغط الدم و/أو بطء ضربات القلب أكثر وضوحًا في المرضى الذين يعانون من نقص حجم الدم أو داء السكري أو ارتفاع ضغط الدم المزمن وفي المرضى المسنين.</p><p dir="RTL">لم يُلاحظ أي أثر إضافي للديناميكا الدوائية في التجارب الإكلينيكية التي تم فيها إعطاء موسعات أخرى للأوعية الدموية أو عوامل خافضة لمعدل ضربات القلب (العوامل المؤثرة بالسلب على الميقاتية) بالتزامن مع بريسيدكس. وبالرغم من ذلك، ينبغي توخي الحذر عند إعطاء هذه العوامل بالتزامن مع بريسيدكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ارتفاع ضغط الدم العابر</strong></p><p dir="RTL">لوحظ حدوث ارتفاع عابر في ضغط الدم بشكل أساسي أثناء إعطاء جرعة التحميل، مرتبط بالآثار الأولية المضيقة للأوعية الدموية المحيطية التي يسببها بريسيدكس. لم يكن علاج ارتفاع ضغط الدم العابر ضروريًا بصفة عامة، بالرغم من أنه قد يكون مفيدًا أن يتم خفض معدل تسريب جرعة التحميل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القابلية للاستثارة</strong></p><p dir="RTL">لوحظ أن بعض المرضى الذين يتلقون بريسيدكس يكونون قابلين للاستثارة ومنتبهين للمحفزات. ولا ينبغي اعتبار ذلك وحده دليلًا على عدم الفعالية في ظل غياب الأعراض والعلامات الإكلينيكية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحملية وزيادة المناعة ضد الدواء</strong></p><p dir="RTL">تم ربط استخدام دكسميديتوميدين لأكثر من ٢٤ ساعة بالتحملية (انخفاض تأثر الجسم بالدواء) وزيادة المناعة ضد الدواء، إلى جانب زيادة في التفاعلات الضارة مرتبطة بالجرعات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فرط الحرارة أو السخونة</strong></p><p dir="RTL">قد يسبب بريسيدكس فرط الحرارة أو السخونة التي قد تكون مقاومة لطرق تبريد الجسم التقليدية، مثل إعطاء السوائل المبردة عبر الوريد والأدوية الخافضة للحرارة. أوقف استخدام بريسيدكس في حالة الاشتباه في حدوث فرط الحرارة أو السخونة المرتبطة بالعقار وراقب المرضى حتى تعود درجة حرارة الجسم إلى طبيعتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخلل الكبدي</strong></p><p dir="RTL">نظرًا لانخفاض تصفية بريسيدكس حسب شدة الخلل الكبدي، ينبغي النظر في تقليل الجرعة لدى المرضى المصابين بخلل في وظائف الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>خطر الوفاة</strong></p><p dir="RTL">ارتبط استخدام دكسميديتوميدين لمدة أكبر من ٢٤ ساعة بزيادة معدل الوفيات بين الأشخاص البالغين من مرضى وحدة العناية المركزة (ICU) ذوي الحالات الحرجة في عمر ٦٣٫٧ عامًا وأصغر مقارنةً بالرعاية المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>الاستعمال لدى الأطفال</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التهدئة للإجراءات غير الجراحية</strong></p><p dir="RTL">تم إثبات سلامة بريسيدكس وفعاليته لدى المرضى الأطفال الذين تتراوح أعمارهم بين شهر واحد وأقل من ١٨ عامًا للتهدئة في أثناء الإجراءات غير الجراحية. يعتمد الاستخدام في هذه الفئة العمرية على تجربة عشوائية واحدة مزدوجة التعمية ومتعددة الجرعات لاختبار السلامة والفعالية لدى المرضى الأطفال الذين لا يخضعون للتنبيب والذين تتراوح أعمارهم بين شهر واحد وأقل من ١٧ عامًا والذين يحتاجون إلى التهدئة قبل الخضوع لفحوص التصوير بالرنين المغناطيسي (MRI) <em>[انظر الدراسات الإكلينيكية]</em>. وقد لوحظت زيادة تكرار بطء التنفس وبطء ضربات القلب وارتفاع ضغط الدم وانخفاض ضغط الدم لدى المرضى الأطفال الذين خضعوا للعلاج ببريسيدكس <em>[انظر ٤٫٨ التأثيرات غير المرغوب فيها]</em>. كان ملف السلامة الشامل لبريسيدكس لدى المرضى الأطفال متسقًا مع ملف السلامة المعروف لدى البالغين <em>[انظر ٤٫٨ التأثيرات غير المرغوب فيها]</em>.</p><p dir="RTL">لم يتم إثبات سلامة بريسيدكس وفعاليته لدى المرضى الأطفال الأصغر من شهر واحد من العمر.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التهدئة في وحدة العناية المركزة</strong></p><p dir="RTL">لم يتم إثبات سلامة وفعالية بريسيدكس للمرضى الأطفال في التهدئة في وحدة العناية المركزة. تم إجراء تجربة واحدة بتعمية القائم بالتقييم على المرضى الأطفال ودراستين مفتوحتي التسمية على حديثي الولادة لتقييم فعالية التهدئة في وحدة العناية المركزة. لم تصل هذه الدراسات لنقطة النهاية الأولية للفعالية ولم تكن بيانات السلامة المقدمة كافية لوصف ملف سلامة بريسيدكس بشكل كامل في هذه الفئة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال لدى المسنين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهدئة في وحدة العناية المركزة</strong></p><p dir="RTL">كان مجموع المرضى البالغ عمرهم ٦٥ عامًا وأكبر في الدراسات الإكلينيكية ٧٢٩ مريضًا. كان مجموع المرضى البالغ عمرهم ٧٥ عامًا وأكبر ٢٠٠ مريض. في المرضى الأكبر من ٦٥ عامًا، لوحظت زيادة معدل حدوث بطء ضربات القلب وانخفاض ضغط الدم بعد إعطائهم بريسيدكس. لذلك يمكن النظر في أمر خفض الجرعة للمرضى الأكبر عمرًا من ٦٥ عامًا.</p><p dir="RTL">لوحظ ارتفاع خطر الوفاة بين الأشخاص البالغين من مرضى وحدة العناية المركزة ذوي الحالات الحرجة في عمر ٦٣٫٧ عامًا وأصغر عند التعرض لدكسميديتوميدين لمدة أكبر من ٢٤ ساعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهدئة الإجرائية</strong></p><p dir="RTL">كان مجموع المرضى البالغ عمرهم ٦٥ عامًا وأكبر في الدراسات الإكلينيكية ١٣١ مريضًا. كان مجموع المرضى البالغ عمرهم ٧٥ عامًا وأكبر ٤٧ مريضًا. حدث انخفاض في ضغط الدم بمعدل أعلى في المرضى المعالَجين ببريسيدكس البالغين من العمر ٦٥ عامًا أو أكبر (٧٢ ٪) والبالغين من العمر ٧٥ عامًا أو أكبر (٧٤ ٪) مقارنةً بالمرضى البالغين من العمر أقل من ٦٥ عامًا (٤٧ ٪). يوصى بجرعة تحميل مخفضة قدرها ٠,٥ ميكروجرام/كلجم تُعطى على مدار ١٠ دقائق وينبغي التفكير في خفض تسريب جرعة المداومة في المرضى البالغين من العمر أكبر من ٦٥ عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&zwnj;التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المواد المخدرة والمهدئات والأدوية المنومة ومسكنات الألم الأفيونية</strong></p><p dir="RTL">من المحتمل أن يؤدي الاستخدام المتزامن لبريسيدكس مع المواد المخدرة والمهدئات والأدوية المنومة ومسكنات الألم الأفيونية إلى تعزيز الآثار. أكدت دراسات محددة حدوث هذه الآثار مع سيفوفلوران وأيزوفلوران وبروبوفول وألفينتانيل وميدازولام. لم يتضح حدوث تفاعلات للحرائك الدوائية بين بريسيدكس وأيزوفلوران وبروبوفول وألفينتانيل وميدازولام. ومع ذلك، نتيجة لتفاعلات الحرائك الدوائية المحتملة، قد يستلزم الأمر خفضًا في جرعة بريسيدكس أو المادة المخدرة أو المهدئ أو المنوم أو مسكن الألم الأفيوني عند استخدام أي منهم بالتزامن مع بريسيدكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المحصرات العصبية العضلية</strong></p><p dir="RTL">في دراسة واحدة لـ١٠ متطوعين بالغين أصحاء، لم يؤد إعطاء بريسيدكس لمدة ٤٥ دقيقة بتركيز في البلازما قدره نانوجرام واحد/مل إلى زيادات ذات أهمية إكلينيكية في حجم الإحصار العصبي العضلي مرتبطة باستعمال روكورونيوم.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التفاعل مع إنزيمات </strong><strong>CYP</strong></p><p dir="RTL">دُرس تثبيط إنزيمات CYP، بما في ذلك إنزيم CYP2B6، بواسطة دكسميديتوميدين في خلايا مُحضنة من ميكروسوم الكبد البشري. وتشير دراسة مجراة في المعمل إلى احتمال وجود تفاعل داخل الجسم بين دكسميديتوميدين والركائز التي تعتمد عملية أيضها على إنزيم CYP2B6 بشكل أساسي.</p><p dir="RTL">ينبغي مراعاة إمكانية زيادة تأثيرات انخفاض ضغط الدم وبطء ضربات القلب لدى المرضى الذين يتلقون منتجات دوائية أخرى تسبب هذه التأثيرات، مثل محصرات بيتا، رغم أن التأثيرات الإضافية في دراسة التفاعل المجراة باستخدام إسمولول كانت بسيطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL"><u>ملخص المخاطر</u></p><p dir="RTL">البيانات المتاحة من التجارب العشوائية المُراقبة المنشورة وتقارير الحالات المُقدمة على مدار عدة عقود من استخدام دكسميديتوميدين عن طريق الوريد أثناء الحمل لم تحدد أي مخاطر مرتبطة بالعقار لحدوث العيوب الولادية الرئيسية والإجهاض؛ لكن حالات التعرض المبلغ عنها حدثت بعد الثلث الأول من الحمل. تستند معظم البيانات المتاحة إلى دراسات تضمنت حالات تعرض في وقت الولادة القيصرية، ولم تحدد هذه الدراسات أي تأثير ضار على نتائج الأم بعد الولادة أو درجات مقياس أبغار للطفل في مرحلة التهادي. تشير البيانات المتاحة إلى أن دكسميديتوميدين ينفذ عبر المشيمة.</p><p dir="RTL">في الدراسات التناسلية على الحيوانات، حدثت سمية جنينية أدت إلى انخفاض قابلية الجنين للحياة وقللت عدد الأجنة الحية عند إعطاء دكسميديتوميدين تحت الجلد للجرذان الحوامل في مرحلة تخلق الأعضاء بجرعات تبلغ ١٬٨ ضعف الجرعة القصوى الموصى بها للبشر (MRHD) البالغة ١٧٫٨ ميكروجرام/كلجم/يوم.</p><p dir="RTL">حدثت سمية تطورية (انخفاض أوزان الجراء وأوزان الجرذان البالغة من النسل، وانخفاض قوة القبضة في الجيل الأول من النسل (F1)، وزيادة حالات الفشل المبكر لعملية انغراس الجنين، وانخفاض قابلية حياة الجيل الثاني من النسل)، وذلك عند حقن الجرذان الحوامل بدكسميديتوميدين تحت الجلد بجرعات أقل من الجرعة الإكلينيكية في المرحلة الأخيرة من الحمل وحتى الرضاعة والفطام (<em>انظر البيانات</em>).</p><p dir="RTL">نسبة الخطر الأساسي المقدرة لحدوث العيوب الولادية الرئيسية والإجهاض غير معروفة لدى تلك الفئة المحددة. تنطوي جميع حالات الحمل على خطر أساسي به حدوث عيوب ولادية أو فقدان الجنين أو نتائج سلبية أخرى. بالنسبة لعامة السكان في الولايات المتحدة، فإن معدل الخطر الأساسي المقدر لحدوث العيوب الولادية الرئيسة والإجهاض في حالات الحمل المعترف بها إكلينيكيًا يبلغ ٢-٤ ٪ و١٥-٢٠ ٪، على التوالي.</p><p dir="RTL"><u>البيانات</u></p><p dir="RTL"><em>بيانات الدراسات على الحيوانات</em></p><p dir="RTL">لوحظت زيادة حالات فقدان الأجنة بعد الانغراس وانخفاض عدد الأجنة الحية مع وجود سمية لدى الأمهات (أي انخفاض وزن الجسم) في دراسة عن التطور المضغي الجنيني للجرذان، حيث تلقت الإناث الحوامل جرعات قدرها ٢٠٠ ميكروجرام/كلجم/يوم من دكسميديتوميدين تحت الجلد (بما يكافئ ١٬٨ ضعف الجرعة القصوى الموصى بها للبشر عن طريق الوريد والبالغة ١٧٫٨ ميكروجرام/كلجم/يوم بناءً على مساحة سطح الجسم [BSA]) في فترة تخلق الأعضاء (أيام الحمل [GD] من ٦ إلى ١٥). ولم يُبلغ عن حدوث أي تشوهات.</p><p dir="RTL">لم تُلحظ أي تشوهات أو سمية مضغية جنينية في دراسة عن التطور المضغي الجنيني للأرانب، حيث تلقت الإناث الحوامل جرعات وصلت إلى ٩٦ ميكروجرام/كلجم/يوم من دكسميديتوميدين عن طريق الوريد (نصف معدل التعرض البشري تقريبًا عند الجرعة القصوى الموصى بها للبشر بناءً على المساحة تحت المنحنى [AUC]) في فترة تخلق الأعضاء (أيام الحمل من ٦ إلى ١٨).</p><p dir="RTL">أُبلغ عن انخفاض أوزان الجراء وأوزان الجرذان البالغة من النسل عند الولادة، وانخفاض قوة القبضة في دراسة عن السمية التطورية لدى الجرذان، حيث تلقت الإناث الحوامل دكسميديتوميدين تحت الجلد بجرعات تبلغ ٨ ميكروجرام/كلجم/يوم (٠٬٠٧ من الجرعة القصوى الموصى بها للبشر بناءً على مساحة سطح الجسم) في المرحلة الأخيرة من الحمل وحتى الرضاعة والفطام (من يوم الحمل ١٦ إلى اليوم ٢٥ بعد الولادة [PND]).</p><p dir="RTL">حدث انخفاض في قابلية حياة الجيل الثاني من النسل وزيادة في حالات الفشل المبكر لعملية الانغراس إلى جانب تأخر التطور الحركي لدى المجموعة التي تلقت ٣٢ ميكروجرام/كلجم/يوم (بما يكافئ أقل من الجرعة الإكلينيكية المُعطاة بناءً على مساحة سطح الجسم) عندما سُمح بتزاوج نسل الجيل الأول. وقصرت هذه الدراسة مدة إعطاء الجرعات من مرحلة إغلاق الحنك الصلب (أيام الحمل ١٥ إلى ١٨) وحتى الفطام، عوضًا عن إعطاء الجرعات من مرحلة الانغراس (أيام الحمل من ٦ إلى ٧) إلى الفطام (اليوم ٢١ بعد الولادة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في دراسة أجريت على الجرذان الحوامل، لوحظ حدوث نقل مشيمي لدكسميديتوميدين عندما تم إعطاء عقار دكسميديتوميدين الموسوم شعاعيًا تحت الجلد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإرضاع</strong></p><p dir="RTL"><u>ملخص المخاطر</u></p><p dir="RTL">تشير الأدبيات العلمية المنشورة المتاحة إلى وجود دكسميديتوميدين في لبن الثدي لدى البشر بعد تلقيه عن طريق الوريد (<em>انظر البيانات</em>). ولا توجد معلومات بشأن آثار دكسميديتوميدين على الطفل الذي يرضع طبيعيًا أو آثاره على إدرار اللبن. انصح السيدات بمراقبة الأطفال الذين يرضعون طبيعيًا تحسبًا لحدوث تهيج. ينبغي مراعاة الفوائد الصحية والتطورية للرضاعة الطبيعية إلى جانب حاجة الأم الإكلينيكية إلى تلقي بريسيدكس وأي آثار ضارة وارد حدوثها على الطفل الذي يرضع طبيعيًا نتيجة بريسيدكس أو الحالة الكامنة لدى الأم.</p><p dir="RTL"><u>البيانات</u></p><p dir="RTL">في دراستين إكلينيكيتين منشورتين، أعطي دكسميديتوميدين عبر الوريد إلى ١٤ سيدة إجمالًا بجرعة قدرها ٦ ميكروجرام/كلجم/ساعة لمدة ١٠ دقائق بعد الولادة، يتبعها تسريب مستمر لجرعة قدرها ٠,٢&ndash;٠,٧ ميكروجرام/كلجم/ساعة. جُمعت عينات من لبن الثدي ودم الأم بعد ٠ و٦ ساعات و١٢ ساعة و٢٤ ساعة من إيقاف دكسميديتوميدين. كانت تركيزات دكسميديتوميدين في البلازما واللبن قابلة للاكتشاف بعد فترة تصل إلى ٦ ساعات لدى معظم المريضات الخاضعات للدراسة، وتصل إلى ١٢ ساعة لدى مريضة واحدة، ولم تكن قابلة للاكتشاف لديهن جميعًا عند مرور ٢٤ ساعة.&nbsp; كانت نسبة التركيز في اللبن إلى البلازما من تركيزات لبن الأم والبلازما أحادية الاقتران عند كل نقطة زمنية تتراوح من ٠,٥٣ إلى ٠,٩٥. كانت تقدير جرعة الرضيع النسبية يتراوح من ٠,٠٢ إلى ٠,٠٩٨ ٪.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>تعليمات الإعطاء</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي أن تكون جرعات بريسيدكس مُخصصة حسب الفرد ويتم معايرتها حسب الاستجابة الإكلينيكية المرغوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; بريسيدكس غير مخصص لعمليات التسريب التي تستمر لأكثر من ٢٤ ساعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; يجب إعطاء بريسيدكس باستخدام جهاز تسريب مُراقب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>الجرعات الموصى بها</strong></p><p dir="RTL"><strong>الجدول ١: الجرعات الموصى بها للمرضى البالغين</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>داعي الاستعمال</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة وطريقة الاستعمال</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>بدء التهدئة في وحدة العناية المركزة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>للمرضى البالغين:</strong> تسريب جرعة تحميل قدرها ميكروجرام واحد/كلجم على مدار ١٠ <strong>دقائق</strong>.</p><p dir="RTL"><strong>للمرضى البالغين المُحولين من العلاج بمهدئ بديل: </strong>قد لا يستلزم الأمر جرعة تحميل.</p><p dir="RTL"><strong>للمرضى الأكبر عمرًا من ٦٥ عامًا:</strong> ينبغي التفكير في خفض الجرعة.</p><p dir="RTL"><strong>للمرضى الذين يعانون من خلل في وظائف الكبد: </strong>ينبغي التفكير في خفض الجرعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>مداومة التهدئة في وحدة العناية المركزة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>للمرضى البالغين: </strong>تسريب جرعة مداومة قدرها من ٠٫٢ إلى ٠٫٧ ميكروجرام/كلجم/<strong>ساعة</strong>. ينبغي تعديل معدل تسريب جرعة المداومة للوصول إلى المستوى المرغوب فيه من التهدئة.</p><p dir="RTL"><strong>للمرضى الأكبر عمرًا من ٦٥ عامًا: </strong>ينبغي التفكير في خفض الجرعة<em>.</em></p><p dir="RTL"><strong>للمرضى الذين يعانون من خلل في وظائف الكبد: </strong>ينبغي التفكير في خفض الجرعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>بدء التهدئة الإجرائية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>للمرضى البالغين: </strong>تسريب جرعة تحميل بمقدار ميكروجرام واحد/كلجم على مدار ١٠ <strong>دقائق</strong>. للإجراءات التي تتطلب تدخلًا جراحيًا بدرجة أقل مثل جراحات العيون، قد يكون تسريب جرعة تحميل قدرها ٠٫٥ ميكروجرام/كلجم يُعطى على مدار ١٠ <strong>دقائق</strong> أمرًا مناسبًا.</p><p dir="RTL"><strong>لإدخال أنبوب تنفسي بالاستعانة بالألياف البصرية أثناء اليقظة للمرضى البالغين: </strong>تسريب جرعة تحميل بمقدار ميكروجرام واحد/كلجم على مدار ١٠ <strong>دقائق</strong>.</p><p dir="RTL"><strong>للمرضى الأكبر عمرًا من ٦٥ عامًا:</strong> تسريب جرعة تحميل بمقدار ٠٫٥ ميكروجرام/كلجم على مدار ١٠ <strong>دقائق</strong><em>.</em></p><p dir="RTL"><strong>للمرضى الذين يعانون من خلل في وظائف الكبد: </strong>ينبغي التفكير في خفض الجرعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>جرعة المداومة الخاصة بالتهدئة الإجرائية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>للمرضى البالغين:</strong> غالبًا ما يبدأ تسريب جرعة المداومة بمقدار ٠٫٦ ميكروجرام/كلجم/<strong>ساعة </strong>وتتم معايرتها للوصول إلى التأثير الإكلينيكي المطلوب بجرعات تتراوح من ٠٫٢ إلى ميكروجرام واحد/كلجم/<strong>ساعة</strong>. ينبغي تعديل معدل تسريب جرعة المداومة للوصول إلى المستوى المُستهدف من التهدئة.</p><p dir="RTL"><strong>لإدخال أنبوب تنفسي بالاستعانة بالألياف البصرية أثناء اليقظة للمرضى البالغين: </strong>يوصى بتسريب جرعة مداومة قدرها ٠٫٧ ميكروجرام/كلجم/<strong>ساعة</strong> حتى يتم تثبيت الأنبوب داخل القصبة الهوائية بإحكام.</p><p dir="RTL"><strong>للمرضى الأكبر عمرًا من ٦٥ عامًا: </strong>ينبغي التفكير في خفض الجرعة<em>.</em></p><p dir="RTL"><strong>للمرضى الذين يعانون من خلل في وظائف الكبد: </strong>ينبغي التفكير في خفض الجرعة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجدول ۲: الجرعات الموصى </strong><strong>بها </strong><strong>للمرضى الأطفال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>داعي الاستعمال</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة وطريقة الاستعمال</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>بدء التهدئة في أثناء الإجراءات غير الجراحية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><u>للمرضى الأطفال:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; من عمر شهر واحد إلى أصغر من عامين: تسريب جرعة تحميل قدرها ١٫٥ ميكروجرام/كلجم على مدار ١٠ <em><u>دقائق</u></em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; من عمر عامين إلى أصغر من ١٨ عامًا: تسريب جرعة تحميل قدرها ٢ ميكروجرام/كلجم على مدار ١٠ <em><u>دقائق</u></em>.</p><p dir="RTL">فكر في تخفيض الجرعة إذا دعت الحاجة إلى ذلك إكلينيكيًا.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>مداومة التهدئة في أثناء الإجراءات غير الجراحية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><u>للمرضى الأطفال:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; من عمر شهر واحد إلى أصغر من ١٨ عامًا: يبدأ تسريب جرعة المداومة عمومًا بجرعة ١٫٥ ميكروجرام/كلجم/<em>ساعة </em>وتتم معايرته لتحقيق التأثير الإكلينيكي المطلوب بجرعة تتراوح من ٠٫٥ إلى ١٫٥ ميكروجرام/كلجم/<em><u>ساعة</u></em>.</p><p dir="RTL">وبحسب ما هو مبرر إكلينيكيًا، قم بمعايرة جرعة المداومة وفقًا للاستجابة الإكلينيكية لكل مريض.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>تعديل الجرعة</strong></p><p dir="RTL">نتيجة لوجود احتمال لحدوث تفاعلات الديناميكا الدوائية، فقد يتطلب الأمر خفض جرعة بريسيدكس أو الأدوية المُصاحبة الأخرى مثل الأدوية المُخدرة أو المُهدئات أو الأدوية المُنومة أو مُسكنات الألم الأفيونية وذلك عندما يتم استعمالهم بشكل متزامن [<em>انظر قسم</em><strong> &quot;الأدوية الأخرى وبريسيدكس</strong>&quot;].</p><p dir="RTL">قد يكون من الضروري التفكير في خفض الجرعات في حالة المرضى <strong>البالغين</strong> الذين يعانون من اختلال في وظائف الكبد وفي حالة المرضى المُسنين [<em>انظر قسم </em>&quot;<strong>تحذيرات واحتياطات&quot;</strong>].</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>تحضير المحلول</strong></p><p dir="RTL">يجب دائمًا الالتزام باتباع أساليب معقمة صارمة أثناء التعامل مع بريسيدكس.</p><p dir="RTL">يجب أن تُفحص منتجات الأدوية المستخدمة عبر الوريد بالنظر للتأكد من عدم وجود أي جسيمات أو تغير للون قبل الاستخدام إذا كان المحلول والحاوية يسمحان بذلك. لا تستخدم المنتج إذا كان لونه متغيرًا أو في حالة وجود مادة مترسبة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بريسيدكس للحقن، ٢٠٠ ميكروجرام/٢ مل (١٠٠ ميكروجرام/مل)</strong></p><p dir="RTL">يجب تخفيف بريسيدكس باستخدام محلول كلوريد صوديوم بتركيز ٠٫٩ ٪ المُخصص للحقن للحصول على التركيز المطلوب (٤ ميكروجرام/مل) قبل الاستخدام. طريقة تحضير المحاليل هي نفسها، سواء لتحضير جرعة التحميل أو جرعة المُداومة.</p><p dir="RTL">لتحضير جرعة التسريب، اسحب ٢ مل من بريسيدكس للحقن، وأضفها إلى ٤٨ مل من محلول كلوريد الصوديوم المُخصص للحقن بتركيز ٠٫٩ ٪ ليُصبح الحجم الكلي ٥٠ مل. قم برجهم برفق ليختلطوا جيدًا.</p><p dir="RTL"><strong>بريسيدكس في محلول كلوريد صوديوم بتركيز ٠٫٩ ٪ المُخصص للحقن، ٢٠٠ ميكروجرام/٥٠ مل (٤ ميكروجرام/مل) و٤٠٠ ميكروجرام/١٠٠ مل (٤ ميكروجرام/مل)</strong></p><p dir="RTL">يتوفر بريسيدكس في محلول كلوريد صوديوم المُخصص للحقن بتركيز ٠٫٩ ٪ داخل حاويات زجاجية تحتوي على محلول هيدروكلوريد دكسميديتوميدين مع محلول كلوريد صوديوم بتركيز ٠٫٩ ٪ في ماء مخلوطة مسبقًا وجاهزة للاستخدام. وهذه المستحضرات لا تحتاج إلى المزيد من التخفيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>الاستعمال مع السوائل الأخرى</strong></p><p dir="RTL">ينبغي عدم إعطاء تسريب بريسيدكس بالتزامن مع الدم أو البلازما من خلال نفس القثطرة الوريدية لأنه لم يثبت التوافق الفيزيائي بين تلك المواد.</p><p dir="RTL">اتضح أن بريسيدكس غير متوافق مع العقاقير التالية عند إعطائه بالتزامن معها: أمفوتيريسين بي، ديازيبام.</p><p dir="RTL">اتضح أن بريسيدكس يتوافق مع السوائل الوريدية التالية عند إعطائه بالتزامن معها:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; كلوريد الصوديوم بتركيز ٠٬٩ ٪ في الماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دكستروز بتركيز ٥ ٪ في الماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; مانيتول بتركيز ٢٠ ٪</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; محلول رينجر اللاكتيكي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; محلول كبريتات المغنيسيوم بتركيز ١٠٠ ملجم/مل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; محلول كلوريد البوتاسيوم بتركيز ٠٫٣ ٪</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>التوافق مع المطاط الطبيعي</strong></p><p dir="RTL">أظهرت دراسات التوافق إمكانية امتصاص بعض أنواع المطاط الطبيعي لبريسيدكس. بالرغم من تحديد جرعة بريسيدكس حسب الأثر المرغوب، يُنصح بأن تكون الأدوات المستخدمة لإعطائه مصنوعة من حشيات مطاط صناعي أو طبيعي مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من بريسيدكس</strong></p><p dir="RTL">تمت دراسة إمكانية تحمل بريسيدكس في دراسة واحدة تم فيها إعطاء أشخاص بالغين أصحاء الجرعات المُوصى بها وجرعات أكبر من الجرعات الموصى بها وهي من ٠٫٢ إلى ٠٫٧ ميكروجرام/كلجم/ساعة. وكان أقصى تركيز تم الوصول إليه في هذه الدراسة حوالي ١٣ ضعف الحد الأعلى للتركيز في النطاق العلاجي. وكانت أكثر التأثيرات البارزة هي الإحصار الأذيني البُطيني من الدرجة الأولى والإحصار القلبي من الدرجة الثانية ولوحظت هذه التأثيرات على الشخصين اللذين تم إعطاؤهما أعلى الجرعات. لم يُلحظ أي ضرر في ديناميكا الدم، حيث اختفى الإحصار الأذيني البطيني والإحصار القلبي تلقائيًا خلال دقيقة واحدة.</p><p dir="RTL">تم إعطاء ٥ أشخاص بالغين جرعات مفرطة من بريسيدكس أثناء دراسات التهدئة في وحدة العناية المركزة. لم يتم الإبلاغ عن ظهور أي أعراض على اثنين من هؤلاء المرضى، تلقى أحد المريضين جرعة تحميل بمقدار ٢ ميكروجرام/كلجم على مدار ١٠ دقائق (ضعف جرعة التحميل الموصى بها) وتلقى المريض الآخر تسريبًا لجرعة مُداومة بمقدار ٠٫٨ ميكروجرام/كلجم/ساعة. أصيب المريضان الآخران اللذان تلقيا جرعة تحميل بمقدار ٢ ميكروجرام/كلجم على مدار ١٠ دقائق، ببطء في ضربات القلب و/أو بانخفاض ضغط الدم. أصيب مريض تلقى جرعة تحميل بالحقن دفعة واحدة من بريسيدكس غير المُخفف (١٩,٤ ميكروجرام/كلجم)، بتوقف في القلب وتم إنعاش قلب المريض بنجاح</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول بريسيدكس</strong></p><p dir="RTL"><strong>السحب</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp; </strong><strong>التهدئة في وحدة العناية المركزة</strong></p><p dir="RTL">مع الاستخدام لمدة تصل إلى ٧ أيام، بغض النظر عن الجرعة، تعرض ١٢ (٥ ٪) شخصًا بالغًا من المُستخدمين لعقار بريسيدكس لحدث واحد على الأقل مرتبط بأعراض انسحاب العقار خلال الـ٢٤ ساعة الأولى بعد التوقف عن استخدام عقار الدراسة وتعرض ٧ (٣ ٪) أشخاص بالغين من المُستخدمين لعقار بريسيدكس لحدث واحد على الأقل خلال الـ٢٤ إلى ٤٨ ساعة بعد انتهاء عقار الدراسة. وكانت الأحداث الأكثر شيوعًا هي الغثيان والقيء والتهيج.</p><p dir="RTL">وفي الأشخاص البالغين، حدثت حالات لسرعة ضربات القلب وارتفاع ضغط الدم تطلبت تدخلًا طبيًا خلال الـ٤٨ ساعة بعد التوقف عن استخدام عقار الدراسة، وذلك بمعدلات حدوث أقل من ٥ ٪.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>التهدئة الإجرائية</strong></p><p dir="RTL">في الأشخاص البالغين، لم تظهر أعراض انسحاب بعد توقف جرعات التسريب قصيرة الأمد لعقار بريسيدكس (أقل من ٦&nbsp;ساعات).</p><p dir="RTL">في المرضى الأطفال، لوحظت أعراض انسحاب عابرة<strong> </strong>خفيفة<strong> </strong>من<strong> </strong>الهذيان أو<strong> </strong>التهيج<strong> </strong>بعد<strong> </strong>التوقف عن التسريب قصير الأمد لبريسيدكس (أقل<strong> </strong>من ساعتين)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، من الممكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت الأحداث الضارة الأكثر شيوعًا التي تم التعرف عليها لدى المرضى الأطفال في أثناء الإجراءات غير الجراحية هي بطء التنفس وبطء ضربات القلب وارتفاع ضغط الدم وانخفاض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم التعرف على التفاعلات الضارة التالية أثناء استخدام بريسيدكس بعد الموافقة عليه. نظرًا لأنه يتم الإبلاغ عن هذه التفاعلات طوعًا من قبل فئات سكانية ذات حجم غير معروف، فليس من الممكن دائمًا عمل تقييم لنسبة تكرار تلك التفاعلات على نحو موثوق به أو إثبات وجود علاقة سببية مع التعرض للدواء.</p><p dir="RTL">كان انخفاض ضغط الدم، وبطء ضربات القلب، وتوقف القلب جيبي المنشأ، وارتفاع ضغط الدم العابر هي التفاعلات الضارة الأكثر شيوعًا المرتبطة باستخدام بريسيدكس بعد الموافقة عليه.</p><p dir="RTL"><strong>التفاعلات الضارة التي حدثت أثناء استخدام بريسيدكس بعد الموافقة عليه</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>التصنيف وفقًا للجهاز أو العضو</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>المصطلح المفضل</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الدم والجهاز الليمفاوي</p></td><td style="vertical-align:top"><p dir="RTL">فقر الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات القلب</p></td><td style="vertical-align:top"><p dir="RTL">اضطراب ضربات القلب، الرجفان الأذيني، الإحصار الأذيني البطيني، بطء ضربات القلب، توقف القلب، الاضطرابات القلبية، الانقباضات الخارجة، احتشاء عضلة القلب، سرعة ضربات القلب فوق البُطينية، سرعة ضربات القلب، عدم انتظام ضربات القلب البُطيني، سرعة ضربات القلب البُطينية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات العين</p></td><td style="vertical-align:top"><p dir="RTL">رؤية الومضات وخلل الرؤية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات المعدية المعوية</p></td><td style="vertical-align:top"><p dir="RTL">ألم البطن، الإسهال، الغثيان، القيء</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة واضطرابات موضع الاستعمال</p></td><td style="vertical-align:top"><p dir="RTL">القشعريرة، فرط السخونة، الألم، السخونة، العطش</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات الكبدية الصفراوية</p></td><td style="vertical-align:top"><p dir="RTL">اختلال وظائف الكبد، فرط بيليروبين الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الفحوصات</p></td><td style="vertical-align:top"><p dir="RTL">زيادة في إنزيم ناقلة أمين الألانين، زيادة في إنزيم ناقلة أمين الأسبارتات، زيادة في مستويات إنزيم الفوسفاتاز القلوي في الدم، زيادة في مستويات يوريا الدم، انعكاس الموجة T في رسم القلب الكهربي، ارتفاع إنزيم ناقلة جاما جلوتامايل، إطالة فترة QT على مُخطط رسم القلب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأيض والتغذية</p></td><td style="vertical-align:top"><p dir="RTL">الحُماض، فرط بوتاسيوم الدم، نقص سكر الدم، نقص حجم الدم، فرط صوديوم الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">التشنج، الدوار، الصداع، الألم العصبي، التهاب الأعصاب، اضطراب الكلام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات النفسية</p></td><td style="vertical-align:top"><p dir="RTL">التهيج، حالة ارتباكية، الهذيان، الهلوسة، التوهم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكلى والجهاز البولي</p></td><td style="vertical-align:top"><p dir="RTL">قلة البول، البُوال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات التنفسية والصدرية والمتواجدة بمنتصف الصدر</p></td><td style="vertical-align:top"><p dir="RTL">انقطاع النفس، التشنج القصبي، ضيق التنفس، فرط ثاني أكسيد الكربون في الدم، نقص التهوية، نقص الأكسجين، الاحتقان الرئوي، الحُماض التنفسي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والنسيج تحت الجلد</p></td><td style="vertical-align:top"><p dir="RTL">فرط العرق، الحكة، الطفح الجلدي، الأرتيكاريا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الإجراءات الجراحية والطبية</p></td><td style="vertical-align:top"><p dir="RTL">التخدير الخفيف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات الوعائية</p></td><td style="vertical-align:top"><p dir="RTL">تقلبات ضغط الدم، النزيف، ارتفاع ضغط الدم، انخفاض ضغط الدم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong><br />إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُخزَّن في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تخلص من الجزء غير المستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد الرمز EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;<br />صلاحية المستحضر ٢٤ شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من أي أدوية عبر مياه الصرف. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي هيدروكلوريد دكسميديتوميدين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لعقار بريسيدكس في محلول كلوريد الصوديوم بتركيز ٠٬٩ ٪ المخصص للحقن، المكون الآخر هو ٩ ملجم من كلوريد الصوديوم في ماء مخصص للحقن.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">بريسيدكس للحقن</p><p dir="RTL">بريسيدكس للحقن (هيدروكلوريد دكسميديتوميدين) ٢٠٠ ميكروجرام/٢ مل (١٠٠ ميكروجرام/مل) هو محلول رائق وعديم اللون. تعتمد قوة التركيز على قاعدة دكسميديتوميدين.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>الحاوية</strong></p></td><td><p dir="RTL"><strong>الحجم</strong></p></td></tr><tr><td><p dir="RTL">علبة تضم ٢٥ قارورة زجاجية شفافة بجرعة فردية</p></td><td><p dir="RTL">٢٠٠ ميكروجرام/٢ مل</p><p dir="RTL">(١٠٠ ميكروجرام/مل)</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">بريسيدكس للحقن (هيدروكلوريد دكسميديتوميدين في محلول كلوريد صوديوم بتركيز ٠٫٩ ٪) (٤ ميكروجرام/مل) هو محلول رائق وعديم اللون. تعتمد قوة التركيز على قاعدة دكسميديتوميدين.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>الحاوية</strong></p></td><td><p dir="RTL"><strong>الحجم</strong></p></td></tr><tr><td><p dir="RTL"><strong>قارورة</strong></p></td><td><p dir="RTL">٢٠٠ ميكروجرام/٥٠ مل<br />(٤ ميكروجرام/مل)</p></td></tr><tr><td><p dir="RTL"><strong>قارورة</strong></p></td><td><p dir="RTL">٤٠٠ ميكروجرام/١٠٠ مل</p><p dir="RTL">(٤ ميكروجرام/مل)</p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك ترخيص التسويق</strong></p><p>Hospira, Inc.,Lake Forest, IL 60045 USA</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p>Hospira Inc, NC27801, Rocky Mount, United states</p><p>او</p><p>Hospira Inc, McPherson, United states</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/كانون الأول ٢٠٢٢.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PRECEDEX (dexmedetomidine hydrochloride) 100 mcg/mL Injection
PRECEDEX (dexmedetomidine hydrochloride) 4 mcg/mL in 0.9% Sodium Chloride Injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PRECEDEX (dexmedetomidine hydrochloride) injection (100 mcg/mL) is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution. PRECEDEX (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection (4 mcg/mL) is a sterile, nonpyrogenic ready to use solution suitable for intravenous infusion. 
PRECEDEX contains dexmedetomidine hydrochloride as the active pharmaceutical ingredient. Dexmedetomidine hydrochloride is a central alpha2-adrenergic agonist. Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine. Dexmedetomidine hydrochloride chemical name is 1H Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, monohydrochloride, (S). Dexmedetomidine hydrochloride has a molecular weight of 236.7 and the empirical formula is C13H16N2 • HCl and the structural formula is:
 
Dexmedetomidine hydrochloride is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89.

PRECEDEX Injection is intended to be used after dilution. It is supplied as a clear, colorless, isotonic solution with a pH between 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride (equivalent to 100 mcg or 0.1 mg of dexmedetomidine) and 9 mg of sodium chloride in water for injection. The solution is preservative-free and contains no additives or chemical stabilizers.

PRECEDEX in 0.9% Sodium Chloride Injection is ready to be used. It is supplied as a clear, colorless, isotonic solution with a pH between 4.5 to 8.0. Each mL contains 4.72 mcg of dexmedetomidine hydrochloride (equivalent to 4 mcg or 0.004 mg of dexmedetomidine) and 9 mg sodium chloride in water for injection. The solution is preservative-free and contains no additives or chemical stabilizers.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Precedex Injection
Precedex Injection, 200 mcg/2 mL dexmedetomidine (100 mcg/mL) in a glass vial. To be used after dilution.
Precedex in 0.9% Sodium Chloride Injection
Precedex Injection, 200 mcg dexmedetomidine/50 mL (4 mcg/mL) dexmedetomidine in a 50 mL vial. Ready to use.
Precedex Injection, 400 mcg dexmedetomidine/100 mL (4 mcg/mL) dexmedetomidine in a 100 mL vial. Ready to use.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Intensive Care Unit Sedation</strong></p><p>&nbsp;</p><p>PRECEDEX is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. PRECEDEX should be administered by continuous infusion not to exceed 24 hours.</p><p>&nbsp;</p><p>PRECEDEX has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue PRECEDEX prior to extubation.</p><p><strong>&nbsp;</strong></p><p><strong>Procedural Sedation</strong></p><p>&nbsp;</p><p>PRECEDEX is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.</p><p>&nbsp;</p><p>PRECEDEX is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Administration Instructions</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX dosing should be individualized and titrated to desired clinical response.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX is not indicated for infusions lasting longer than 24 hours.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; PRECEDEX should be administered using a controlled infusion device.</p><p><strong>&nbsp;</strong></p><p><strong>Recommended Dosage</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Recommended Dosage in Adult Patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>INDICATION</strong></p></td><td style="vertical-align:top"><p><strong>DOSAGE AND ADMINISTRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><u>For adult patients:</u> a loading infusion of one mcg/kg over 10 <em><u>minutes</u></em>.</p><p><u>For adult patients being converted from alternate sedative therapy:</u><strong> </strong>a loading dose may not be required.</p><p><u>For patients over 65 years of age: </u>Consider a dose reduction<em> </em>[<em>see Use in Specific Populations (4.6)</em>].</p><p><u>For adult patients with impaired hepatic-function:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6), Clinical Pharmacology (5.2)</em>].</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><u>For adult patients:</u><strong> </strong>a maintenance infusion of 0.2 to 0.7 mcg/kg/<em><u>hour</u></em>. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation.</p><p><u>For patients over 65 years of age:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6)</em>]<em>.</em></p><p><u>For adult patients with impaired hepatic function:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6), Clinical Pharmacology (5.2)</em>]</p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><u>For adult patients:</u><strong> </strong>a loading infusion of one mcg/kg over 10 <em><u>minutes</u></em>. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5&nbsp;mcg/kg given over 10 <em><u>minutes</u></em> may be suitable.</p><p><u>For awake fiberoptic intubation in adult patients:</u><strong> </strong>a loading infusion of one&nbsp;mcg/kg over 10 <em><u>minutes</u></em>.</p><p><u>For patients over 65 years of age:</u> a loading infusion of 0.5 mcg/kg over 10&nbsp;<em>minutes</em> [<em>see Use in Specific Populations (4.6)</em>]<em>.</em></p><p><u>For adult patients with impaired hepatic function:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6), Clinical Pharmacology (5.2)</em>].</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><u>For adult patients:</u> the maintenance infusion is generally initiated at 0.6&nbsp;mcg/kg/<em><u>hour</u></em> and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<em><u>hour</u></em>. Adjust the rate of the maintenance infusion to achieve the targeted level of sedation.</p><p><u>For awake fiberoptic intubation in adult patients:</u><strong> </strong>a maintenance infusion of 0.7&nbsp;mcg/kg/<em>hour</em> is recommended until the endotracheal tube is secured.</p><p><u>For patients over 65 years of age:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6)</em>]<em>.</em></p><p><u>For adult patients with impaired hepatic function:</u><strong> </strong>Consider a dose reduction [<em>see Use in Specific Populations (4.6), Clinical Pharmacology (5.2)</em>].</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 2: Recommended Dosage in Pediatric Patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>INDICATION</p></td><td style="vertical-align:top"><p>DOSAGE AND ADMINISTRATION</p></td></tr><tr><td style="vertical-align:top"><p>Initiation of Sedation During Non‑invasive Procedures</p></td><td style="vertical-align:top"><p><u>For pediatric patients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 month to less than 2 years: a loading infusion of 1.5&nbsp;mcg/kg over 10 <em><u>minutes</u></em><u>.</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 to less than 18 years: a loading infusion of 2 mcg/kg over 10 <em><u>minutes</u></em><u>.</u></p><p>Consider a reduction in dosage if clinically indicated.</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of Sedation During Non-invasive Procedures</p></td><td style="vertical-align:top"><p><u>For pediatric patients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 month to less than 18 years: the maintenance infusion is generally initiated at 1.5&nbsp;mcg/kg/<em><u>hour</u></em> and titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/<em><u>hour</u></em><u>.</u></p><p>As clinically warranted, titrate the maintenance dose to individual patient clinical response.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Dosage Adjustment</strong></p><p>&nbsp;</p><p>Due to possible pharmacodynamic interactions, a reduction in dosage of PRECEDEX or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [<em>see Drug Interactions&nbsp;(4.5)</em>].</p><p>&nbsp;</p><p>Dosage reductions may need to be considered for <strong>adult</strong> patients with hepatic impairment, and geriatric patients [<em>see Warnings and Precautions (4.4), Use in Specific Populations (4.6), Clinical Pharmacology&nbsp;(5.2)</em>].</p><p><strong>&nbsp;</strong></p><p><strong>Preparation of Solution</strong></p><p>&nbsp;</p><p>Strict aseptic technique must always be maintained during handling of PRECEDEX.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if product is discolored or if precipitate matter is present.</p><p>&nbsp;</p><p><strong><u>PRECEDEX Injection, 200 mcg/2 mL (100 mcg/mL)</u></strong></p><p>PRECEDEX must be diluted with 0.9% sodium chloride injection to achieve required concentration (4&nbsp;mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.</p><p>To prepare the infusion, withdraw 2 mL of PRECEDEX Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.</p><p>&nbsp;</p><p><strong><u>PRECEDEX in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4&nbsp;mcg/mL) and 400 mcg/100 mL (4 mcg/mL)</u></strong></p><p>PRECEDEX in 0.9% Sodium Chloride Injection is supplied in glass containers containing a premixed, ready to use dexmedetomidine hydrochloride solution in 0.9% sodium chloride in water. No further dilution of these preparations is necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Administration with Other Fluids</strong></p><p>&nbsp;</p><p>PRECEDEX infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.</p><p>PRECEDEX has been shown to be incompatible when administered with the following drugs: amphotericin&nbsp;B, diazepam.</p><p>PRECEDEX has been shown to be compatible when administered with the following intravenous fluids:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% sodium chloride in water</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 5% dextrose in water</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 20% mannitol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Lactated Ringer&rsquo;s solution</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 100 mg/mL magnesium sulfate solution</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; 0.3% potassium chloride solution</p><p><strong>&nbsp;</strong></p><p><strong>Compatibility with Natural Rubber</strong></p><p>Compatibility studies have demonstrated the potential for absorption of PRECEDEX to some types of natural rubber. Although PRECEDEX is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drug Administration</p><p>&nbsp;</p><p>PRECEDEX should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of PRECEDEX, patients should be continuously monitored while receiving PRECEDEX.</p><p><strong>&nbsp;</strong></p><p><strong>Hypotension, Bradycardia, and Sinus Arrest</strong></p><p>Clinically significant episodes of bradycardia and sinus arrest have been reported with PRECEDEX administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.</p><p>Reports of hypotension and bradycardia have been associated with PRECEDEX infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of PRECEDEX, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because PRECEDEX has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of PRECEDEX-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.</p><p>Caution should be exercised when administering PRECEDEX to patients with advanced heart block and/or severe ventricular dysfunction. Because PRECEDEX decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients.</p><p>In clinical trials where other vasodilators or negative chronotropic agents were co-administered with PRECEDEX an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with PRECEDEX.</p><p><strong>&nbsp;</strong></p><p><strong>Transient Hypertension</strong></p><p>Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of PRECEDEX. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.</p><p>&nbsp;</p><p><strong>Arousability</strong></p><p>Some patients receiving PRECEDEX have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>Withdrawal</strong></p><p><u>Intensive Care Unit Sedation</u></p><p>With administration up to 7 days, regardless of dose, 12 (5%) PRECEDEX adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) PRECEDEX adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation <em>[see 4.8 Undesirable effects]</em>.</p><p>In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of &lt;5%.</p><p><u>Procedural Sedation</u></p><p>In adult subjects, withdrawal symptoms were not seen after discontinuation of short term infusions of PRECEDEX (&lt;6&nbsp;hours).</p><p>In pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation were seen after discontinuation of short term infusions of PRECEDEX (&lt;2 hours) <em>[see 4.8 Undesirable effects]</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Tolerance and Tachyphylaxis</strong></p><p>Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [<em>see 4.8Undesirable effects</em>].</p><p>&nbsp;</p><p><strong>Hyperthermia or Pyrexia</strong></p><p>PRECEDEX may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue PRECEDEX if drug‑related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalizes.</p><p>&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>Since PRECEDEX clearance decreases with increasing severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [<em>see Dosage and Administration (4.2)</em>].</p><p>&nbsp;</p><p><strong>Risk of Mortality</strong></p><p>Use of dexmedetomidine greater than 24&nbsp;hours has been associated with an increased mortality in critically ill adult intensive care unit (ICU) patients 63.7&nbsp;years of age and younger compared to usual care <em>[see Clinical Studies]. </em></p><p>&nbsp;</p><p><strong>General Precautions</strong></p><p>&nbsp;</p><p>Users should be ready to use an alternative sedative for acute control of agitation or during procedures, especially during the first few hours of treatment.</p><p>PRECEDEX should not be used as an induction agent for intubation or to provide sedation during muscle relaxant use.</p><p>Dexmedetomidine lacks the anticonvulsant action of some other sedatives and so will not suppress underlying seizure activity.</p><p>&nbsp;</p><p><strong>USE IN SPECIFIC POPULATIONS</strong></p><p>&nbsp;</p><p><strong>Pediatric Use</strong></p><p><u>Sedation for Non-Invasive Procedures</u></p><p>The safety and efficacy of PRECEDEX have been established in pediatric patients 1&nbsp;month to less than 18&nbsp;years of age for sedation during non-invasive procedures. Use in this age group is based on one randomized double-blind, dose-ranging safety and efficacy trial in non-intubated pediatric patients 1 month to less than 17&nbsp;years of age who required sedation prior to undergoing MRI scans <em>[see Clinical Studies]</em>. An increase in frequency of bradypnea, bradycardia, hypertension and hypotension was observed in pediatric patients treated with PRECEDEX <em>[see 4.8 Undesirable effects]. </em>The overall safety profile of PRECEDEX in pediatric patients was consistent with the known safety profile in adults<em> [see 4.8 Undesirable effects]</em>.</p><p>The safety and effectiveness of PRECEDEX have not been established in pediatric patients less than 1 month of age.</p><p><u>&nbsp;</u></p><p><u>ICU Sedation</u></p><p>The safety and efficacy of PRECEDEX have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of PRECEDEX for these patient populations.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric Use</strong></p><p><u>Intensive Care Unit Sedation</u></p><p>A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of PRECEDEX [<em>see Warnings and Precautions (4.4)</em>]. Therefore, a dose reduction may be considered in patients over 65 years of age [<em>see Dosage and Administration (4.2) and Clinical Pharmacology (5.2)</em>]<em>.</em></p><p>An increased mortality risk has been seen for critically ill adult ICU patients 63.7&nbsp;years of age and younger when the exposure to dexmedetomidine was greater than 24&nbsp;hours <em>[see Clinical Studies (5.1)]</em></p><p><strong>&nbsp;</strong></p><p><u>Procedural Sedation</u></p><p>A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75&nbsp;years of age and over. Hypotension occurred in a higher incidence in PRECEDEX-treated patients 65&nbsp;years or older (72%) and 75 years or older (74%) as compared to patients &lt;65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anesthetics, Sedatives, Hypnotics, Opioids</p><p>Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between PRECEDEX and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX or the concomitant anesthetic, sedative, hypnotic or opioid may be required.</p><p><strong>&nbsp;</strong></p><p><strong>Neuromuscular Blockers</strong></p><p>In one study of 10 healthy adult volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration.</p><p>&nbsp;</p><p><strong>Interaction with CYP Enzymes</strong></p><p><strong>&nbsp;</strong></p><p>Inhibition of CYP enzymes including CYP2B6 by dexmedetomidine has been studied in human liver microsome incubations. In vitro study suggests that interaction potential in vivo exists between dexmedetomidine and substrates with dominant CYP2B6 metabolism.</p><p>&nbsp;</p><p>The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinal products causing these effects, for example beta-blockers, although additional effects in an interaction study with esmolol were modest.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>&nbsp;</p><p><u>Risk Summary</u></p><p>Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta.</p><p>In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8&nbsp;mcg/kg/day.</p><p>Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning <em>(see Data)</em>.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%, respectively.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e. decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6&nbsp;to 15). No malformations were reported.</p><p>No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD&nbsp;6 to 18).</p><p>Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8&nbsp;mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD&nbsp;16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32&nbsp;mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD&nbsp;6&nbsp;to 7) to weaning (PND&nbsp;21).</p><p>&nbsp;</p><p>In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously. Lactation</p><p><u>Risk Summary</u></p><p>Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration <em>(see Data)</em>. There is no information regarding the effects of dexmedetomidine on the breastfed infant or the effects on milk production. Advise women to monitor the breastfed infant for irritability. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for PRECEDEX and any potential adverse effects on the breastfed infant from PRECEDEX or from the underlying condition.</p><p><u>Data</u></p><p>In two published clinical studies, a total of 14 women were given intravenous dexmedetomidine 6 mcg/kg/hour for 10&nbsp;minutes after delivery followed by continuous infusion of 0.2&ndash;0.7 mcg/kg/hour. Breast milk and maternal blood samples were collected at 0, 6, 12, and 24 hours after discontinuation of dexmedetomidine. Plasma and milk dexmedetomidine concentrations were detectable up to 6 hours in most subjects, up to 12&nbsp;hours in one subject and undetectable in all at 24 hours. The milk-to-plasma ratio from single paired maternal milk and plasma concentrations at each time point ranged from 0.53 to 0.95. The relative infant dose was estimated to range from 0.02 to 0.098%.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension, bradycardia and sinus arrest [<em>see Warnings and Precautions (4.4)</em>]</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Transient hypertension [<em>see Warnings and Precautions (4.4)</em>]</p><p>&nbsp;</p><p>Clinical Trials Experience</p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Most common treatment-emergent adverse reactions, occurring in greater than 2% of adult patients in both Intensive Care Unit and procedural sedation studies include hypotension, bradycardia and dry mouth.</p><p><strong>&nbsp;</strong></p><p><u>Intensive Care Unit Sedation</u></p><p>Adverse reaction information is derived from the continuous infusion trials of PRECEDEX for sedation in the Intensive Care Unit setting in which 1007 adult patients received PRECEDEX. The mean total dose was 7.4&nbsp;mcg/kg (range: 0.8 to 84.1), mean dose per hour was 0.5 mcg/kg/hr (range: 0.1 to 6.0) and the mean duration of infusion of 15.9 hours (range: 0.2 to 157.2). The population was between 17 to 88 years of age, 43% &ge;65 years of age, 77% male and 93% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of &gt;2% are provided in Table 3. The most frequent adverse reactions were hypotension, bradycardia and dry mouth [<em>see Warnings and Precautions (4.4)</em>].</p><p><strong>Table 3: Adverse Reactions with an Incidence &gt;2%-Adult Intensive Care Unit Sedation Population &lt;24&nbsp;hours*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:bottom"><p><strong>All PRECEDEX</strong></p><p><strong>(N = 1007)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Randomized PRECEDEX</strong></p><p><strong>(N = 798)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(N = 400)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Propofol</strong></p><p><strong>(N = 188)</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>11%</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Atrial Fibrillation</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>7%</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Dry Mouth</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Hypovolemia</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Atelectasis</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Pleural Effusion</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperthermia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Post-procedural Hemorrhage</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary Edema</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Acidosis</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Urine Output Decreased</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Sinus Tachycardia</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Ventricular Tachycardia</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Wheezing</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Edema Peripheral</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; 26 subjects in the all PRECEDEX group and 10 subjects in the randomized PRECEDEX group had exposure for greater than 24 hours.</p><p>&nbsp;</p><p>Adverse reaction information was also derived from the placebo-controlled, continuous infusion trials of PRECEDEX for sedation in the surgical intensive care unit setting in which 387 adult patients received PRECEDEX for less than 24 hours. The most frequently observed treatment-emergent adverse events included hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and anemia (see Table 4).</p><p><strong>Table 4: Treatment-Emergent Adverse Events Occurring in &gt;1% Of All Dexmedetomidine-Treated Adult Patients in the Randomized Placebo-Controlled Continuous Infusion &lt;24 Hours ICU Sedation Studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>Randomized Dexmedetomidine</strong></p><p><strong>(N = 387)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N = 379)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>18%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Atrial Fibrillation</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Dry Mouth</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Rigors</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperpyrexia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Acidosis</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Pleural Effusion</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Oliguria</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Thirst</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr></tbody></table><p>&nbsp;</p><p>In a controlled clinical trial, PRECEDEX was compared to midazolam for ICU sedation exceeding 24 hours duration in adult patients. Key treatment emergent adverse events occurring in dexmedetomidine or midazolam treated adult patients in the randomized active comparator continuous infusion long-term intensive care unit sedation study are provided in Table 5. The number (%) of adult subjects who had a dose-related increase in treatment-emergent adverse events by maintenance adjusted dose rate range in the PRECEDEX group is provided in Table 6.</p><p>&nbsp;</p><p><strong>Table 5: Key Treatment-Emergent Adverse Events Occurring in Dexmedetomidine- or Midazolam‑Treated Adult Patients in the Randomized Active Comparator Continuous Infusion Long-Term Intensive Care Unit Sedation Study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dexmedetomidine</strong></p><p><strong>(N = 244)</strong></p></td><td style="vertical-align:top"><p><strong>Midazolam</strong></p><p><strong>(N = 122)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension<sup>1</sup></p></td><td style="vertical-align:top"><p>56%</p></td><td style="vertical-align:top"><p>56%</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension Requiring Intervention</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia<sup>2</sup></p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia Requiring Intervention</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Systolic Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>42%</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia<sup>4</sup></p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>44%</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia Requiring Intervention</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Diastolic Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension Requiring Intervention<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>30%</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycemia</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory Failure</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Renal Failure Acute</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Acute Respiratory Distress Syndrome</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Generalized Edema</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesemia</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>7%</p></td></tr></tbody></table><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes any type of hypertension.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hypotension was defined in absolute terms as Systolic blood pressure of &lt;80 mmHg or Diastolic blood pressure of &lt;50&nbsp;mmHg or in relative terms as &le;30% lower than pre-study drug infusion value.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia was defined in absolute terms as &lt;40 bpm or in relative terms as &le;30% lower than pre-study drug infusion value.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hypertension was defined in absolute terms as Systolic blood pressure &gt;180 mmHg or Diastolic blood pressure of &gt;100&nbsp;mmHg or in relative terms as &ge;30% higher than pre-study drug infusion value.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia was defined in absolute terms as &gt;120 bpm or in relative terms as &ge;30% greater than pre-study drug infusion value.</p><p>&nbsp;</p><p>The following adverse events occurred between 2 and 5% for PRECEDEX and Midazolam, respectively: renal failure acute (2.5%, 0.8%), acute respiratory distress syndrome (2.5%, 0.8%), and respiratory failure (4.5%, 3.3%).</p><p><strong>&nbsp;</strong></p><p><strong>Table 6: Number (%) of Adult Subjects Who Had a Dose-Related Increase in Treatment Emergent Adverse Events by Maintenance Adjusted Dose Rate Range in the PRECEDEX Group</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PRECEDEX mcg/kg/hr</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>&le;0.7*</strong></p><p><strong>(N = 95)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;0.7 to &le;1.1*</strong></p><p><strong>(N = 78)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;1.1*</strong></p><p><strong>(N = 71)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>Edema Peripheral</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>7%</p></td></tr><tr><td style="vertical-align:top"><p>Atrial Fibrillation</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory Failure</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Acute Respiratory Distress Syndrome</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>9%</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; Average maintenance dose over the entire study drug administration</p><p><strong>&nbsp;</strong></p><p><u>Adult </u><u>Procedural Sedation</u></p><p>Adverse reaction information is derived from the two trials for adult procedural sedation [<em>see Clinical Studies</em>] in which 318 adult patients received PRECEDEX. The mean total dose was 1.6 mcg/kg (range: 0.5&nbsp;to&nbsp;6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5&nbsp;hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% &ge;65 years of age, 52% male and 61% Caucasian.</p><p>&nbsp;</p><p>Treatment-emergent adverse reactions occurring in adult at an incidence of &gt;2% are provided in Table 7. The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [<em>see Warnings and Precautions (4.4)</em>]. Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between PRECEDEX and comparator groups in both studies.</p><p>&nbsp;</p><p>Table 7: Adverse Reactions With an Incidence &gt; 2%&mdash; Adult Procedural Sedation Population</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:bottom"><p><strong>PRECEDEX</strong></p><p><strong>(N = 318)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(N = 113)</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Hypotension<sup>1</sup></p></td><td style="vertical-align:top"><p>54%</p></td><td style="vertical-align:top"><p>30%</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory Depression<sup>2</sup></p></td><td style="vertical-align:top"><p>37%</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia<sup>3</sup></p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>4</sup></p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia<sup>5</sup></p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>17%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Dry Mouth</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia<sup>6</sup></p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Bradypnea</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>4%</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension was defined in absolute and relative terms as Systolic blood pressure of &lt;80 mmHg or &le;30% lower than pre-study drug infusion value, or Diastolic blood pressure of &lt;50 mmHg.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) &lt;8 beats per minute or &gt; 25% decrease from baseline.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia was defined in absolute and relative terms as &lt;40 beats per minute or &le;30% lower than pre-study drug infusion value. Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug <em>[see Clinical Studies]</em>.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension was defined in absolute and relative terms as Systolic blood pressure &gt;180 mmHg or &ge;30% higher than pre-study drug infusion value or Diastolic blood pressure of &gt;100 mmHg.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia was defined in absolute and relative terms as &gt;120 beats per minute or &ge;30% greater than pre-study drug infusion value.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypoxia was defined in absolute and relative terms as SpO<sub>2</sub> &lt;90% or 10% decrease from baseline.</p><p>&nbsp;</p><p><u>Pediatric Sedation for Magnetic Resonance Imaging</u></p><p>Adverse reaction information is derived from a trial for sedation of pediatric procedural during a non‑invasive procedure <em>[see Clinical Studies]</em> in which 122 pediatric patients aged 1 month to less than 17 years undergoing magnetic resonance imaging (MRI) scans received PRECEDEX. In pediatric patients 1 month to less than 2 years old, the median total dose for the PRECEDEX low, middle, and high dose treatment groups was 8.30, 18.90, and 22.75 mcg, respectively. The median duration of treatment ranged from 52.5 to 69 minutes across treatment groups. In pediatric patients 2 to less than 17 years old, the median total dose for the PRECEDEX low, middle, and high dose treatment groups was 21.30, 43.90, and 80.25&nbsp;mcg, respectively. The median duration of treatment ranged from 56.5 to 66 minutes across treatment groups.</p><p>&nbsp;</p><p>All-causality treatment-emergent adverse reactions occurring in the combined age group of pediatric patients during the procedure at an incidence of &gt;5% are provided in Table 8. The most frequent treatment-emergent adverse events were bradypnea, bradycardia, hypertension, and hypotension <em>[see Warnings and Precautions (4.4)]</em>. In the combined age group and in each age group, increased incidence in bradycardia and hypertension was observed with increasing PRECEDEX dose. Mild transient withdrawal symptoms of emergence delirium or agitation occurred in 3 of 122 patients after discontinuation of PRECEDEX infusion <em>[see Warnings and Precautions (4.4)]</em>. All reported treatment‑emergent adverse reactions were mild to moderate in severity and the majority resolved without medical intervention. No subject in the study required airway intervention, including a jaw thrust or insertion of a nasal or oral airway. A similar profile was observed in the pediatric patients 1 month to less than 2 years old and in pediatric patients 2 to less than 17&nbsp;years old. Pre‑specified criteria for the vital signs to be reported as adverse events are footnoted below the table.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Table 8: Treatment-Emergent Adverse Events with Incidence &gt;5%&mdash;Pediatric Patients During Non-invasive Procedure</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>PRECEDEX</strong></p><p><strong>Low Dose</strong></p><p><strong>(N = 42)</strong></p></td><td style="vertical-align:top"><p><strong>PRECEDEX</strong></p><p><strong>Middle Dose</strong></p><p><strong>(N = 42)</strong></p></td><td style="vertical-align:top"><p><strong>PRECEDEX</strong></p><p><strong>High Dose</strong></p><p><strong>(N = 38)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(N = 122)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number (%) of Pediatric Patients</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bradypnea<sup>1</sup></p></td><td style="vertical-align:top"><p>33 (79)</p></td><td style="vertical-align:top"><p>27 (64)</p></td><td style="vertical-align:top"><p>22 (58)</p></td><td style="vertical-align:top"><p>82 (67)</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia<sup>2</sup></p></td><td style="vertical-align:top"><p>24 (57)</p></td><td style="vertical-align:top"><p>24 (57)</p></td><td style="vertical-align:top"><p>27 (71)</p></td><td style="vertical-align:top"><p>75 (62)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>11 (26)</p></td><td style="vertical-align:top"><p>17 (41)</p></td><td style="vertical-align:top"><p>18 (47)</p></td><td style="vertical-align:top"><p>46 (38)</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension<sup>4</sup></p></td><td style="vertical-align:top"><p>13 (31)</p></td><td style="vertical-align:top"><p>11 (26)</p></td><td style="vertical-align:top"><p>6 (16)</p></td><td style="vertical-align:top"><p>30 (25)</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia<sup>5</sup></p></td><td style="vertical-align:top"><p>6 (14)</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>1 (3)</p></td><td style="vertical-align:top"><p>10 (8)</p></td></tr><tr><td style="vertical-align:top"><p>Diastolic Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>4 (11)</p></td><td style="vertical-align:top"><p>10 (8)</p></td></tr><tr><td style="vertical-align:top"><p>Systolic Hypertension<sup>3</sup></p></td><td style="vertical-align:top"><p>1 (2)</p></td><td style="vertical-align:top"><p>5 (12)</p></td><td style="vertical-align:top"><p>3 (8)</p></td><td style="vertical-align:top"><p>9 (7)</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>1 (2)</p></td><td style="vertical-align:top"><p>1 (3)</p></td><td style="vertical-align:top"><p>5 (4)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>N = Number of pediatric patients evaluable for adverse events.</p><p><sup>1</sup> Bradypnea was defined as respiratory rate &lt;1<sup>st</sup> centile of the age adjusted normal range.</p><p><sup>2</sup> Bradycardia was defined as a decrease in HR of 30% from baseline or absolute HR &le;1<sup>st</sup> centile of the age adjusted normal range.</p><p><sup>3</sup> For pediatric patients 1 month to less than 1 year old, hypertension was defined as supine systolic blood pressure &ge;104 mm/Hg and/or diastolic blood pressure &ge;56 mmHg measurements. For pediatric patients 1 to less than 17 years old: hypertension was defined as supine systolic blood pressure and/or diastolic blood pressure measurements &ge;95<sup>th</sup> percentile for gender, age, and height.</p><p><sup>4</sup> Hypotension was defined as a decrease in systolic blood pressure &ge;30% from baseline.</p><p><sup>5</sup> Hypoxia was defined as oxygen saturation &lt;90% for any duration.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during post approval use of PRECEDEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Hypotension and bradycardia were the most common adverse reactions associated with the use of PRECEDEX during post approval use of the drug.</p><p>&nbsp;</p><p><strong>Table 9: Adverse Reactions Experienced During Post-Approval Use of PRECEDEX</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>Anemia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac Disorders</p></td><td style="vertical-align:top"><p>Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Eye Disorders</p></td><td style="vertical-align:top"><p>Photopsia, visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhea, nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Chills, hyperpyrexia, pain, pyrexia, thirst</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>Hepatic function abnormal, hyperbilirubinemia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Agitation, confusional state, delirium, hallucination, illusion</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>Oliguria, polyuria</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>Hyperhidrosis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Surgical and Medical Procedures</p></td><td style="vertical-align:top"><p>Light anesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>Blood pressure fluctuation, hemorrhage, hypertension, hypotension</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Controlled Substance</p><p>PRECEDEX (dexmedetomidine hydrochloride) is not a controlled substance.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dependence</strong></p><p>The dependence potential of PRECEDEX has not been studied in humans. However, since studies in rodents and primates have demonstrated that PRECEDEX exhibits pharmacologic actions similar to those of clonidine, it is possible that PRECEDEX may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation<em> </em>[<em>see Warnings and Precautions (4.4)</em>].</p><p>&nbsp;</p><p><strong>Overdosage</strong></p><p>The tolerability of PRECEDEX was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hr. The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute.</p><p>Five adult patients received an overdose of PRECEDEX in the intensive care unit sedation studies. Two of these patients had no symptoms reported; one patient received a 2 mcg/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8&nbsp;mcg/kg/hr. Two other patients who received a 2 mcg/kg loading dose over 10 minutes, experienced bradycardia and/or hypotension. One patient who received a loading bolus dose of undiluted PRECEDEX (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action</p><p>PRECEDEX is a relatively selective alpha<sub>2</sub>-adrenergic agonist with sedative properties. Alpha<sub>2</sub> selectivity is observed in animals following slow intravenous infusion of low and medium doses (10‑300&nbsp;mcg/kg). Both alpha<sub>1</sub> and alpha<sub>2</sub> activity is observed following slow intravenous infusion of high doses (&ge;1000&nbsp;mcg/kg) or with rapid intravenous administration.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacodynamics</strong></p><p>In a study in healthy adult volunteers (N = 10), respiratory rate and oxygen saturation remained within normal limits and there was no evidence of respiratory depression when PRECEDEX was administered by intravenous infusion at doses within the recommended dose range (0.2&ndash;0.7 mcg/kg/hr).</p><p>&nbsp;</p><p><strong>CLINICAL STUDIES</strong></p><p>The safety and efficacy of PRECEDEX has been evaluated in four randomized, double-blind, placebo-controlled multicenter clinical trials in 1,185 adult patients.</p><p><strong>&nbsp;</strong></p><p><strong>Intensive Care Unit Sedation</strong></p><p>Two randomized, double-blind, parallel-group, placebo-controlled multicenter clinical trials included 754&nbsp;adult patients being treated in a surgical intensive care unit. All patients were initially intubated and received mechanical ventilation. These trials evaluated the sedative properties of PRECEDEX by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardized Ramsay Sedation Scale) between PRECEDEX and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay Level of Sedation Scale is displayed in Table 10.</p><p><strong>Table 10: Ramsay Level of Sedation Scale</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Clinical Score</strong></p></td><td style="vertical-align:top"><p><strong>Level of Sedation Achieved</strong></p></td></tr></thead><tbody><tr><td><p>6</p></td><td><p>Asleep, no response</p></td></tr><tr><td><p>5</p></td><td><p>Asleep, sluggish response to light glabellar tap or loud auditory stimulus</p></td></tr><tr><td><p>4</p></td><td><p>Asleep, but with brisk response to light glabellar tap or loud auditory stimulus</p></td></tr><tr><td><p>3</p></td><td><p>Patient responds to commands</p></td></tr><tr><td><p>2</p></td><td><p>Patient cooperative, oriented, and tranquil</p></td></tr><tr><td><p>1</p></td><td><p>Patient anxious, agitated, or restless</p></td></tr></tbody></table><p>In the first study, 175 adult patients were randomized to receive placebo and 178 to receive PRECEDEX by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7&nbsp;mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of &ge;3. Patients were allowed to receive &ldquo;rescue&rdquo; midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomized to placebo received significantly more midazolam than patients randomized to PRECEDEX (see Table 11).</p><p>A second prospective primary analysis assessed the sedative effects of PRECEDEX by comparing the percentage of adult patients who achieved a Ramsay sedation score of &ge;3 during intubation without the use of additional rescue medication. A significantly greater percentage of adult patients in the PRECEDEX group maintained a Ramsay sedation score of &ge;3 without receiving any midazolam rescue compared to the placebo group (see Table 11).</p><p><strong>Table 11: Midazolam Use as Rescue Medication During Intubation (ITT)</strong></p><p><strong>Study One</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N = 175)</strong></p></td><td style="vertical-align:top"><p><strong>PRECEDEX</strong></p><p><strong>(N = 178)</strong></p></td><td style="vertical-align:bottom"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean Total Dose (mg) of Midazolam</strong></p></td><td style="vertical-align:top"><p>19 mg</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>0.0011*</p></td></tr><tr><td style="vertical-align:top"><p>Standard deviation</p></td><td style="vertical-align:top"><p>53 mg</p></td><td style="vertical-align:top"><p>19 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Categorized Midazolam Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 mg</p></td><td style="vertical-align:top"><p>43 (25%)</p></td><td style="vertical-align:top"><p>108 (61%)</p></td><td style="vertical-align:top"><p>&lt;0.001**</p></td></tr><tr><td style="vertical-align:top"><p>0&ndash;4 mg</p></td><td style="vertical-align:top"><p>34 (19%)</p></td><td style="vertical-align:top"><p>36 (20%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;4 mg</p></td><td style="vertical-align:top"><p>98 (56%)</p></td><td style="vertical-align:top"><p>34 (19%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>ITT (intent-to-treat) population includes all randomized patients.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; ANOVA model with treatment center.</p><p>**&nbsp;&nbsp; Chi-square.</p><p>A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the PRECEDEX and placebo groups. On average, PRECEDEX-treated patients received less morphine sulfate for pain than placebo‑treated patients (0.47 versus 0.83 mg/h). In addition, 44% (79 of 178 patients) of PRECEDEX patients received no morphine sulfate for pain versus 19% (33 of 175 patients) in the placebo group.</p><p>In a second study, 198 adult patients were randomized to receive placebo and 203 to receive PRECEDEX by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7&nbsp;mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion was adjusted to maintain a Ramsay sedation score of &ge;3. Patients were allowed to receive &ldquo;rescue&rdquo; propofol as needed to augment the study drug infusion. In addition, morphine sulfate was administered as needed for pain. The primary outcome measure for this study was the total amount of rescue medication (propofol) needed to maintain sedation as specified while intubated.</p><p>Adult patients randomized to placebo received significantly more propofol than adult patients randomized to PRECEDEX (see Table 12).</p><p>A significantly greater percentage of adult patients in the PRECEDEX group compared to the placebo group maintained a Ramsay sedation score of &ge;3 without receiving any propofol rescue (see Table 12).</p><p><strong>Table 12: Propofol Use as Rescue Medication During Intubation (ITT)</strong></p><p><strong>Study Two</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N = 198)</strong></p></td><td style="vertical-align:top"><p><strong>PRECEDEX</strong></p><p><strong>(N = 203)</strong></p></td><td style="vertical-align:bottom"><p><strong>p-value</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Mean Total Dose (mg) of Propofol</strong></p></td><td style="vertical-align:top"><p>513 mg</p></td><td style="vertical-align:top"><p>72 mg</p></td><td style="vertical-align:top"><p>&lt;0.0001*</p></td></tr><tr><td style="vertical-align:top"><p>Standard deviation</p></td><td style="vertical-align:top"><p>782 mg</p></td><td style="vertical-align:top"><p>249 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Categorized Propofol Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 mg</p></td><td style="vertical-align:top"><p>47 (24%)</p></td><td style="vertical-align:top"><p>122 (60%)</p></td><td style="vertical-align:top"><p>&lt;0.001**</p></td></tr><tr><td style="vertical-align:top"><p>0&ndash;50 mg</p></td><td style="vertical-align:top"><p>30 (15%)</p></td><td style="vertical-align:top"><p>43 (21%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;50 mg</p></td><td style="vertical-align:top"><p>121 (61%)</p></td><td style="vertical-align:top"><p>38 (19%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; ANOVA model with treatment center.</p><p>**&nbsp;&nbsp; Chi-square.</p><p>A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the PRECEDEX and placebo groups. On average, PRECEDEX-treated patients received less morphine sulfate for pain than placebo‑treated patients (0.43 versus 0.89 mg/h). In addition, 41% (83 of 203 patients) of PRECEDEX patients received no morphine sulfate for pain versus 15% (30 of 198 patients) in the placebo group.</p><p>In a controlled clinical trial, PRECEDEX was compared to midazolam for ICU sedation exceeding 24 hours duration. PRECEDEX was not shown to be superior to midazolam for the primary efficacy endpoint, the percent of time patients were adequately sedated (81% versus 81%). In addition, administration of PRECEDEX for longer than 24 hours was associated with tolerance, tachyphylaxis, and a dose-related increase in adverse events <em>[see 4.8 Undesirable effects]</em>.</p><p><u>SPICE III Study</u></p><p>In a published randomized controlled trial (Sedation Practice in Intensive Care Evaluation (SPICE) III trial) of 3,904 critically ill adult ICU patients, dexmedetomidine was used as primary sedative and compared to usual patient care. There was no overall difference in the primary outcome of 90-day mortality between the dexmedetomidine and usual care group (mortality 29.1% in both groups). In exploratory subgroup analyses, dexmedetomidine was associated with a decreased mortality in patients with age greater than the median age of 63.7&nbsp;years (risk difference -4.4; 95% confidence interval -8.7 to -0.1) compared to usual care. Conversely, dexmedetomidine was associated with an increased mortality in patients with age less than or equal to the median age of 63.7&nbsp;years (risk difference 4.4; 95% confidence interval 0.8 to 7.9) compared to usual care.</p><p>In the published study, exposure to dexmedetomidine was greater than 24&nbsp;hours with a median duration of treatment of 2.56&nbsp;days (interquartile range, 1.10 to 5.23). The administration of dexmedetomidine was continued as clinically required for up to 28&nbsp;days after randomization. The significance of these findings is unknown, but they should be weighed against the expected clinical benefit of dexmedetomidine compared to alternative sedatives in patients less than or equal to 63.7&nbsp;years of age.</p><p>Procedural Sedation</p><p><u>Adult Patients</u></p><p>The safety and efficacy of PRECEDEX for sedation of non-intubated adult patients prior to and/or during surgical and other procedures was evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials. Study 1 evaluated the sedative properties of PRECEDEX in adult patients having a variety of elective surgeries/procedures performed under monitored anesthesia care. Study 2 evaluated PRECEDEX in adult patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure.</p><p>In Study 1, the sedative properties of PRECEDEX were evaluated by comparing the percent of adult patients not requiring rescue midazolam to achieve a specified level of sedation using the standardized Observer&rsquo;s Assessment of Alertness/Sedation Scale (see Table 13).</p><p><strong>Table 13: Observer&rsquo;s Assessment of Alertness/Sedation</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Assessment Categories</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Responsiveness</strong></p></td><td style="vertical-align:bottom"><p><strong>Speech</strong></p></td><td style="vertical-align:bottom"><p><strong>Facial Expression</strong></p></td><td style="vertical-align:bottom"><p><strong>Eyes</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Composite Score</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Responds readily to name spoken in normal tone</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>Clear, no ptosis</p></td><td colspan="2" style="vertical-align:top"><p>5 (alert)</p></td></tr><tr><td style="vertical-align:bottom"><p>Lethargic response to name spoken in normal tone</p></td><td style="vertical-align:top"><p>Mild slowing or thickening</p></td><td style="vertical-align:top"><p>Mild relaxation</p></td><td style="vertical-align:top"><p>Glazed or mild ptosis (less than half the eye)</p></td><td colspan="2" style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:bottom"><p>Responds only after name is called loudly and/or repeatedly</p></td><td style="vertical-align:top"><p>Slurring or prominent slowing</p></td><td style="vertical-align:top"><p>Marked relaxation</p><p>(slack jaw)</p></td><td style="vertical-align:top"><p>Glazed and marked ptosis (half the eye or more)</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:bottom"><p>Responds only after mild prodding or shaking</p></td><td style="vertical-align:top"><p>Few recognizable words</p></td><td><p>&ndash;</p></td><td><p>&ndash;</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:bottom"><p>Does not respond to mild prodding or shaking</p></td><td><p>&ndash;</p></td><td><p>&ndash;</p></td><td><p>&ndash;</p></td><td colspan="2" style="vertical-align:top"><p>1 (deep sleep)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Adult patients were randomized to receive a loading infusion of either PRECEDEX 1 mcg/kg, PRECEDEX 0.5&nbsp;mcg/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 mcg/kg/hr. The maintenance infusion of study drug could be titrated from 0.2 mcg/kg/hr to 1&nbsp;mcg/kg/hr to achieve the targeted sedation score (Observer&rsquo;s Assessment of Alertness/Sedation Scale &le;4). Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an Observer&rsquo;s Assessment of Alertness/Sedation Scale &le;4. After achieving the desired level of sedation, a local or regional anesthetic block was performed. Demographic characteristics were similar between the PRECEDEX and comparator groups. Efficacy results showed that PRECEDEX was more effective than the comparator group when used to sedate non‑intubated patients requiring monitored anesthesia care during surgical and other procedures (see Table 14).</p><p>In Study 2, the sedative properties of PRECEDEX were evaluated by comparing the percent of adult patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay Sedation Scale score &ge;2 (see Table 10). Adult patients were randomized to receive a loading infusion of PRECEDEX 1 mcg/kg or placebo (normal saline) given over 10 minutes and followed by a fixed maintenance infusion of 0.7&nbsp;mcg/kg/hr. After achieving the desired level of sedation, topicalization of the airway occurred. Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain a Ramsay Sedation Scale &ge;2. Demographic characteristics were similar between the PRECEDEX and comparator groups. For efficacy results see Table 14.</p><p><strong>Table 14: Key Efficacy Results of Adult Procedural Sedation Studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Study</strong></p></td><td style="vertical-align:bottom"><p><strong>Loading Infusion Treatment Arm</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of Patients Enrolled<sup>a</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>% Not Requiring Midazolam Rescue</strong></p></td><td style="vertical-align:bottom"><p><strong>Confidence<sup>b</sup> Interval on the Difference vs. Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Mean (SD) Total Dose (mg) of Rescue Midazolam Required</strong></p></td><td style="vertical-align:bottom"><p><strong>Confidence<sup>b</sup> Intervals of the Mean Rescue Dose</strong></p></td></tr><tr><td rowspan="3"><p><strong>Study&nbsp;1</strong></p></td><td style="vertical-align:top"><p>Dexmedetomidine 0.5 mcg/kg</p></td><td><p>134</p></td><td><p>40</p></td><td><p>37 (27, 48)</p></td><td><p>1.4 (1.7)</p></td><td><p>-2.7</p><p>(-3.4, -2.0)</p></td></tr><tr><td style="vertical-align:top"><p>Dexmedetomidine 1 mcg/kg</p></td><td style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>51 (40, 62)</p></td><td style="vertical-align:top"><p>0.9 (1.5)</p></td><td style="vertical-align:top"><p>-3.1</p><p>(-3.8, -2.5)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&ndash;</p></td><td style="vertical-align:top"><p>4.1 (3.0)</p></td><td style="vertical-align:top"><p>&ndash;</p></td></tr><tr><td rowspan="2"><p><strong>Study&nbsp;2</strong></p></td><td style="vertical-align:top"><p>Dexmedetomidine 1 mcg/kg</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>39 (20, 57)</p></td><td style="vertical-align:top"><p>1.1 (1.5)</p></td><td style="vertical-align:top"><p>-1.8</p><p>(-2.7, -0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&ndash;</p></td><td style="vertical-align:top"><p>2.9 (3.0)</p></td><td style="vertical-align:top"><p>&ndash;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on ITT population defined as all randomized and treated patients.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Normal approximation to the binomial with continuity correction.</p><p>&nbsp;</p><p><u>Pediatric Patients</u></p><p>The safety and efficacy of PRECEDEX for sedation of non-intubated pediatric patients aged 1 month to less than 17&nbsp;years undergoing MRI scans was evaluated in one randomized, double-blind, dose-ranging, dose‑controlled multicenter clinical trial utilizing 3 different PRECEDEX dosages. The sedative properties of PRECEDEX were evaluated by age group and by the percent of pediatric patients at the high dose level versus the low dose level who did not require concomitant propofol to complete the MRI scan.</p><p>A total of 122 pediatric patients were randomized to the PRECEDEX low dose group (42 of 122), the middle dose group (42 of 122) or the high dose treatment group (38 of 122). All patients received a PRECEDEX loading dose infusion over 10 minutes followed by a maintenance infusion for the duration of the MRI scan (Table 15). If an adequate level of sedation was not achieved within 5 minutes after the start of the PRECEDEX maintenance infusion, patients could receive concomitant propofol as needed based on clinical judgment to achieve and/or maintain adequate sedation.</p><p><strong>&nbsp;</strong></p><p><strong>Table 15: PRECEDEX Loading and Maintenance Doses</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>High Dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Middle Dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Low Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age </strong></p></td><td style="vertical-align:top"><p><strong>Loading Dose </strong></p><p><strong>(10 min)</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p></td><td style="vertical-align:top"><p><strong>Loading Dose </strong></p><p><strong>(10 min)</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p></td><td style="vertical-align:top"><p><strong>Loading Dose </strong></p><p><strong>(10 min)</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>1 month to less than 2&nbsp;years</p></td><td style="vertical-align:top"><p>1.5&nbsp;mcg/kg</p></td><td style="vertical-align:top"><p>1.5&nbsp;mcg/kg/h</p></td><td style="vertical-align:top"><p>1&nbsp;mcg/kg</p></td><td style="vertical-align:top"><p>1&nbsp;mcg/kg/h</p></td><td style="vertical-align:top"><p>0.5&nbsp;mcg/kg</p></td><td style="vertical-align:top"><p>0.5&nbsp;mcg/kg/h</p></td></tr><tr><td style="vertical-align:top"><p>2 to less than 17 years</p></td><td style="vertical-align:top"><p>2&nbsp;mcg/kg</p></td><td style="vertical-align:top"><p>1.5&nbsp;mcg/kg/h</p></td><td style="vertical-align:top"><p>1.2&nbsp;mcg /kg</p></td><td style="vertical-align:top"><p>1&nbsp;mcg/kg/h</p></td><td style="vertical-align:top"><p>0.5&nbsp;mcg/kg</p></td><td style="vertical-align:top"><p>0.5&nbsp;mcg kg/h</p></td></tr></tbody></table><p>The primary efficacy results from this pediatric procedural sedation study are summarized in Table 16. In the combined age group, the percent of pediatric patients not requiring concomitant propofol was 14.3% (6/42) in the low dose group and 63.2% (24/38) in the high dose group. The percentage of patients at the PRECEDEX high dose who completed the MRI without concomitant propofol was statistically greater than the percentage in the PRECEDEX low dose group (p&lt;0.001).</p><p><strong>&nbsp;</strong></p><p><strong>Table 16: Percent of Pediatric Patients not Requiring Concomitant Propofol by Age Group and Overall</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age Group</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>High Dose</strong></p></td><td style="vertical-align:top"><p><strong>Middle Dose</strong></p></td><td style="vertical-align:top"><p><strong>Low Dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>High Dose vs Low Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p><p><strong>95% CI<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p><p><strong>95% CI<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p><p><strong>95% CI<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>Odds Ratio</strong></p><p><strong>95% CI<sup>**</sup></strong></p></td><td style="vertical-align:top"><p><strong>p-value<sup>**</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>1 month to less than 2 years</p></td><td style="vertical-align:top"><p>N=59</p></td><td style="vertical-align:top"><p>9/18 (50.0%)</p><p>(0.26, 0.74)</p></td><td style="vertical-align:top"><p>2/21 (9.5%)</p><p>(0.01, 0.30)</p></td><td style="vertical-align:top"><p>2/20 (15.0%)</p><p>(0.03, 0.38)</p></td><td style="vertical-align:top"><p>0.18 (0.04, 0.82)</p></td><td style="vertical-align:top"><p>0.022</p></td></tr><tr><td style="vertical-align:top"><p>2 to less than 17 years</p></td><td style="vertical-align:top"><p>N=63</p></td><td style="vertical-align:top"><p>15/20 (75.0%)</p><p>(0.51, 0.91)</p></td><td style="vertical-align:top"><p>13/21 (61.9%)</p><p>(0.38, 0.82)</p></td><td style="vertical-align:top"><p>3/22 (13.6%)</p><p>(0.03, 0.35)</p></td><td style="vertical-align:top"><p>0.05 (0.01, 0.26)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall</strong></p></td><td style="vertical-align:top"><p>N=122</p></td><td style="vertical-align:top"><p>24/38 (63.2%)</p><p>(0.46, 0.78)</p></td><td style="vertical-align:top"><p>15/42 (35.7%)</p><p>(0.22, 0.52)</p></td><td style="vertical-align:top"><p>6/42 (14.3%)</p><p>(0.05, 0.29)</p></td><td style="vertical-align:top"><p>0.10 (0.03, 0.29)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p><sup>*</sup> Exact 95% CI of proportion of subjects not requiring propofol in each dose level.</p><p><sup>**</sup> p-values; CI is confidence interval of odds ratio.</p><p>&nbsp;</p><p>Secondarily, the sedative properties were also evaluated by examining the percent of time at a target sedation score using the Pediatric Sedation State Scale (PSSS). The PSSS is a validated 6-point scale specifically designed for evaluating pediatric patients undergoing sedation for diagnostic and therapeutic procedures. The PSSS measures the effectiveness and quality of procedural sedation in children. The target sedation level was indicated by a PSSS score of 2 (i.e., patient is quiet [asleep or awake], not moving during procedure, has no frown [or brow furrow] indicating pain or anxiety and no verbalization of any complaint).</p><p>In the PRECEDEX high dose group, pediatric patients in both the combined and individual age group were at the target sedation rating scale score (PSSS of 2) for a mean &gt;87% of the time during the PRECEDEX maintenance infusion. In both the combined and individual age group, an increase in the percentage of time at the target sedation rating scale score (PSSS of 2) was observed with increasing PRECEDEX dosage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intravenous administration to adult, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t<sub>1/2</sub>) of approximately 6 minutes; a terminal elimination half-life (t<sub>1/2</sub>) of approximately 2 hours; and steady-state volume of distribution (V<sub>ss</sub>) of approximately 118 liters. Clearance is estimated to be approximately 39 L/h. The mean body weight associated with this clearance estimate was 72 kg.</p><p>&nbsp;</p><p>Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered to adult by intravenous infusion for up to 24 hours. Table 17 shows the main pharmacokinetic parameters when PRECEDEX was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25&nbsp;ng/mL) for 24 hours.</p><p>&nbsp;</p><p><strong>Table 17: Mean &plusmn; SD Pharmacokinetic Parameters in Adult</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="4" style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td colspan="4"><p><strong>Loading Infusion (min)/Total Infusion Duration (hrs)</strong></p></td></tr><tr><td><p><strong>10 min/12 hrs</strong></p></td><td><p><strong>10 min/24 hrs</strong></p></td><td><p><strong>10 min/24 hrs</strong></p></td><td><p><strong>35 min/24 hrs</strong></p></td></tr><tr><td colspan="4"><p><strong>Dexmedetomidine</strong><strong> Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr)</strong></p></td></tr><tr><td><p><strong>0.3/0.17</strong></p></td><td><p><strong>0.3/0.17</strong></p></td><td><p><strong>0.6/0.33</strong></p></td><td><p><strong>1.25/0.70</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>t<sub>1/2</sub>*, hour</strong></p></td><td><p>1.78 &plusmn; 0.30</p></td><td><p>2.22 &plusmn; 0.59</p></td><td><p>2.23 &plusmn; 0.21</p></td><td><p>2.50 &plusmn; 0.61</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>CL, liter/hour</strong></p></td><td><p>46.3 &plusmn; 8.3</p></td><td><p>43.1 &plusmn; 6.5</p></td><td><p>35.3 &plusmn; 6.8</p></td><td><p>36.5 &plusmn; 7.5</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>V<sub>ss</sub>, liter </strong></p></td><td><p>88.7 &plusmn; 22.9</p></td><td><p>102.4 &plusmn; 20.3</p></td><td><p>93.6 &plusmn; 17.0</p></td><td><p>99.6 &plusmn; 17.8</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Avg C<sub>ss</sub><sup>#</sup>, ng/mL</strong></p></td><td><p>0.27 &plusmn; 0.05</p></td><td><p>0.27 &plusmn; 0.05</p></td><td><p>0.67 &plusmn; 0.10</p></td><td><p>1.37 &plusmn; 0.20</p></td></tr></tbody></table><p>Abbreviations: t<sub>1/2</sub> = half‑life, CL = clearance, V<sub>ss</sub> = steady‑state volume of distribution.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; Presented as harmonic mean and pseudo standard deviation.</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp; Mean C<sub>ss</sub> = Average steady-state concentration of Dexmedetomidine. The mean C<sub>ss</sub> was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions.</p><p>&nbsp;</p><p>The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively.</p><p>Dexmedetomidine pharmacokinetic parameters in adults after PRECEDEX maintenance doses of 0.2 to 1.4&nbsp;mcg/kg/hr for &gt;24 hours were similar to the PK parameters after PRECEDEX maintenance dosing for &lt; 24 hours in other studies. The values for clearance (CL), volume of distribution (V), and t<sub>1/2</sub> were 39.4 L/hr, 152 L, and 2.67 hours, respectively.</p><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p>The steady-state volume of distribution (V<sub>ss</sub>) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects. The average protein binding was 94% and was constant across the different plasma concentrations tested. Protein binding was similar in males and females. The fraction of PRECEDEX that was bound to plasma proteins was significantly decreased in subjects with hepatic impairment compared to healthy subjects.</p><p>&nbsp;</p><p>The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored <em>in vitro</em>, and negligible changes in the plasma protein binding of PRECEDEX were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by PRECEDEX was explored <em>in</em> <em>vitro</em> and none of these compounds appeared to be significantly displaced by PRECEDEX.</p><p><strong>&nbsp;</strong></p><p>Elimination</p><p><strong>&nbsp;</strong></p><p><em>Metabolism</em></p><p>Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19) of dexmedetomidine to generate 3‑hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3‑carboxy‑dexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N‑methyl‑dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O‑glucuronide.</p><p>&nbsp;</p><p><em>Excretion</em></p><p>The terminal elimination half-life (t<sub>1/2</sub>) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N‑glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy-dexmedetomidine, the glucuronide of 3‑hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N-methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine. The N-Methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified.</p><p><u>Specific Populations</u></p><p><em>Male and Female Patients</em></p><p>There was no observed difference in PRECEDEX pharmacokinetics due to gender.</p><p><strong>&nbsp;</strong></p><p><em>Geriatric Patients</em></p><p>The pharmacokinetic profile of PRECEDEX was not altered by age. There were no differences in the pharmacokinetics of PRECEDEX in young (18&ndash;40 years), middle age (41&ndash;65 years), and elderly (&gt;65 years) subjects.</p><p><strong>&nbsp;</strong></p><p><em>Pediatric Patients</em></p><p>A population PK analysis was conducted with data collected from mechanically ventilated pediatric patients less than 17 years of age from 4 clinical studies. A linear 2-compartment model was found to best characterize the pooled dexmedetomidine concentration data. Mean PK parameters for each age group are summarized in Table 18.</p><p><strong>&nbsp;</strong></p><p><strong>Table 18: Geometric Mean Point Estimates and 95% Confidence Intervals of PK Parameters by Pediatric Age Group</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age Group</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>CL (L/h)</strong></p></td><td style="vertical-align:top"><p><strong>Vc (L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1 to less than 6 months</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>6.94 (5.46, 8.81)</p></td><td style="vertical-align:top"><p>4.34 (3.25, 5.81)</p></td></tr><tr><td style="vertical-align:top"><p>6 to less than 12 months</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>8.15 (7.01, 9.47)</p></td><td style="vertical-align:top"><p>7.29 (5.57, 9.53)</p></td></tr><tr><td style="vertical-align:top"><p>12 to less than 24 months</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>10.76 (9.09, 12.74)</p></td><td style="vertical-align:top"><p>7.35 (5.59, 9.67)</p></td></tr><tr><td style="vertical-align:top"><p>2 to less than 6 years</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>15.89 (14.00, 18.04)</p></td><td style="vertical-align:top"><p>13.78 (10.66, 17.83)</p></td></tr><tr><td style="vertical-align:top"><p>6 to less than 17 years</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>24.45 (19.34, 30.92)</p></td><td style="vertical-align:top"><p>24.47 (17.06, 35.10)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviations: CL = plasma clearance, Vc = volume of the central compartment.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Patients with Hepatic Impairment</em></p><p>In adult subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values for PRECEDEX were lower than in healthy subjects. The mean clearance values for patients with mild, moderate, and severe hepatic impairment were 74%, 64% and 53% of those observed in the normal healthy adult subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy adult subjects, respectively.</p><p>&nbsp;</p><p>Although PRECEDEX is dosed to effect, it may be necessary to consider dose reduction in subjects with hepatic impairment [<em>see Dosage and Administration (4.2), Warnings and Precautions (4.4)</em>].</p><p><em>&nbsp;</em></p><p><em>Patients with Renal Impairment</em></p><p>Dexmedetomidine pharmacokinetics (C<sub>max</sub>, T<sub>max</sub>, AUC, t<sub>1/2</sub>, CL, and V<sub>ss</sub>) were not significantly different in patients with severe renal impairment (creatinine clearance: &lt;30 mL/min) compared to healthy subjects.</p><p><strong>&nbsp;</strong></p><p><u>Drug Interaction </u><u>Studies</u></p><p><em>In vitro</em> studies: <em>In vitro</em> studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis</u></p><p>Animal carcinogenicity studies have not been performed with dexmedetomidine.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>Dexmedetomidine was not mutagenic <em>in vitro</em>, in either the bacterial reverse mutation assay (<em>E. coli</em> and <em>Salmonella</em> <em>typhimurium</em>) or the mammalian cell forward mutation assay (mouse lymphoma). Dexmedetomidine was clastogenic in the <em>in vitro</em> human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation. In contrast, dexmedetomidine was not clastogenic in the <em>in&nbsp;vitro</em> human lymphocyte chromosome aberration test with or without human S9 metabolic activation. Although dexmedetomidine was clastogenic in an <em>in vivo</em> mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice.</p><p>&nbsp;</p><p><u>Impairment of Fertility</u></p><p>Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m<sup>2</sup> basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females.</p><p><strong>&nbsp;</strong></p><p><strong>Animal Toxicology and/or Pharmacology</strong></p><p>There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single dose of dexmedetomidine compared to saline control. However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose-dependent adrenal suppression.</p><p><strong>&nbsp;</strong></p><p>PATIENT COUNSELING INFORMATION</p><p>PRECEDEX is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of PRECEDEX and as clinically appropriate after discontinuation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When PRECEDEX is infused for more than 6 hours, patients should be informed to report nervousness, agitation, and headaches that may occur for up to 48 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of PRECEDEX such as: weakness, confusion, excessive sweating, weight loss, abdominal pain, salt cravings, diarrhea, constipation, dizziness or light-headedness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Advise breastfeeding mothers who were exposed to PRECEDEX to monitor breastfed neonates for irritability <em>[see Use in Specific Populations]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride.</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use PRECEDEX after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.

Shelf life: 24 months.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Discard unused portion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PRECEDEX (dexmedetomidine hydrochloride) injection 200 mcg/2 mL (100 mcg/mL) is clear and colorless. The strength is based on the dexmedetomidine base.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:66%"><tbody><tr><td><p><strong>Container</strong></p></td><td><p><strong>Size</strong></p></td></tr><tr><td><p>Tray of 25 single dose clear glass vials</p></td><td><p>200 mcg/2 mL</p><p>(100 mcg/mL)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>PRECEDEX (dexmedetomidine hydrochloride in 0.9% Sodium Chloride) injection (4 mcg/mL) is clear and colorless. &nbsp;The strength is based on the dexmedetomidine base.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:66%"><tbody><tr><td><p><strong>Container</strong></p></td><td><p><strong>Size</strong></p></td></tr><tr><td><p>Vial</p></td><td><p>200 mcg/50 mL</p><p>(4 mcg/mL)</p></td></tr><tr><td><p>Vial</p></td><td><p>400 mcg/100 mL</p><p>(4 mcg/mL)</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p><em>&nbsp;</em></p><p>Do not use if product is discolored or if precipitate matter is present.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Hospira, Inc.
Lake Forest, IL 60045 United states

MANUFACUTRED BY
Hospira Inc, NC 27801, Rocky Mount, United states
Or
Hospira Inc., McPherson, United states

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>